Document:

Exhibit 10.2

 

SHARE PURCHASE AGREEMENT

 

This Share Purchase Agreement (this “Agreement”)
is made and entered into as of the 9 day of January, 2020, by and between Bonus BioGroup Ltd., an Israeli Public Company
520039777 (the “Company”) and Wize Pharma Inc., a Delaware corporation (the “Investor”
or “Wize”).

 

WHEREAS, the Company is a public
company registered in Israel, whose securities are traded on the Tel Aviv Stock Exchange Ltd. (the “TASE”);

 

WHEREAS, the Board of Directors
of the Company (the “Board”) has (A) determined that it is in the best interests of the Company to issue the
Bonus Shares at the Closing in consideration for: (i) at the Closing, US$3,700,000 (three million and seven hundred thousand US
dollars), in immediately available funds, free and clear of any restrictions; (ii) at the Milestone Closing, US$3,700,000 (three
million and seven hundred thousand US dollars), in immediately available funds, free and clear of any restrictions; and (iii) at
the Closing, the Right to LO2A Proceeds (as defined in the Exchange Agreement), all under the terms and conditions described in
this Agreement and the Exchange Agreement (collectively referred to as the “Transaction”), and (B) approved the
execution and performance of this Agreement, the Exchange Agreement and the other transactions contemplated under the Transaction;

 

WHEREAS, concurrently with the execution
of this Agreement, the parties hereto are entering into the Exchange Agreement;

 

WHEREAS, simultaneously with the
execution and delivery of this Agreement, and as a condition and material inducement to Wize’s willingness to enter into
this Agreement, certain key shareholders of the Company are entering into support undertakings with Wize, each in the form attached
hereto as Exhibit A (the “Support Agreements”);

 

WHEREAS, simultaneously with the
execution and delivery of this Agreement, and as a condition and material inducement to Wize’s willingness to enter into
this Agreement, the Chief Executive Officer of the Company is entering into a proprietary information undertaking with the Company,
in the form attached hereto as Exhibit B (the “IP Undertaking”); and

 

WHEREAS, simultaneously with the
execution and delivery of this Agreement, the Investor, the Company and the Escrow Agent are entering into an escrow agreement
in the form attached hereto as Exhibit C (the “Escrow Agreement”), whereby, among other things,
(i) at or prior to Closing, the Investor shall deposit the Cash Consideration with the Escrow Agent, (ii) at the Closing, the Escrow
Agent shall transfer the Initial Cash Consideration to the Company, and (iii) at the Milestone Closing, the Escrow Agent shall
transfer the Milestone Cash Consideration to the Company, all under the terms and conditions set forth in this Agreement and the
Escrow Agreement;

 

     

     

    

 

NOW, THEREFORE, it has been acknowledged,
stipulated and agreed between the parties as follows:

 

1. Definitions

 

For purposes of this Agreement,
the following terms will have the following meanings:

 

	“Agreed Amount”	Sixteen Million and Four Hundred Thousand US dollars (US$16,400,000)
	“Agreed Advance PPS”	The average closing price of the Ordinary Shares shares on TASE during 14 trading days prior to the issuance date of the Advance Shares.
	“Agreed PPS”	NIS 0.50 (in words: fifty agorot of NIS). 
	“Affiliate”	With respect to any Person, another Person which directly or indirectly Controls, is Controlled by or is under common Control with such Person. For the purposes of this definition, “Control” shall have the meaning as set out in the ISL.
	“Bonus Shares”	A number of Ordinary Shares equal to the quotient obtained by dividing (A) the Agreed Amount expressed in NIS (based on the Exchange Rate as of the Business Day immediately prior to the date hereof) by (B) the Agreed PPS, with fractional shares rounded up to the nearest whole share; subject to adjustment in the case of split, reclassification, dividends and the like as more fully detailed herein if occurs following the date hereof.
	“Business Day”	a day on which the principal banks located in Tel Aviv and New York are open for business during normal banking hours.
	“Cash Consideration”	The sum of (A) US$3,700,000 (three million and seven hundred thousand US dollars) (the “Initial Cash Consideration”) and (B) US$3,700,000 (three million and seven hundred thousand US dollars) (the “Milestone Cash Consideration”). 
	“Company’s Bank”	Bank Leumi Le-Israel BM, Leumi Tech Business Branch NO.864, 15 Hamenofim St. Herzliya 4672566, Israel. 
	“Company’s Bank Account”	
        Account number 86100027 in the
        name of Bonus BioGroup Ltd., that is held at the Company’s Bank and/or

        Swift / TID: LUMIILITXXX

        IBAN: IL770108640000086100027

	“Escrow Agent”	IBI Trust Management, or such other entity mutually agreed between the parties.
	“Exchange Agreement”	That certain Exchange Agreement entered into by and between the Company and Wize, of even date herewith.
	“Exchange Rate”	the rate of exchange reported by the Bank of Israel for the US Dollar.
	“Initial Shares” 	means the Initial PIPE Shares and the LO2A Shares.

 

    2

     

    

 

	“ISL”	The Israeli Securities Law, 5728 – 1968, together with the regulations promulgated thereunder.
	“LO2A Shares”	50% (fifty percent) of the Bonus Shares.
	“Material Adverse Effect”	Any (A) material adverse effect or change, on or affecting  (i) the business, properties, assets, liabilities, operations, results of operations, condition (financial or otherwise) or prospects of the Company and of the Subsidiaries (as defined below), taken as a whole, or (ii) the transactions contemplated hereby or the other Transaction Documents or by the agreements and instruments to be entered into in connection herewith or therewith, or (iii) on the authority or ability of the Company to perform its obligations under the Transaction Documents, or (iv) on the legality, validity, binding effect or enforceability of any of the Transaction Documents; provided, however, that “Material Adverse Effect” shall not include any event, occurrence, fact, condition or change, directly or indirectly, arising out of or attributable to: (i) general economic or political conditions; (ii) conditions generally affecting the industries in which the Company operates; (iii) any changes in financial, banking or securities markets in general, including any disruption thereof and any decline in the price of any market index or any change in prevailing interest rates; (iv) acts of war (whether or not declared), armed hostilities or terrorism, or the escalation or worsening thereof; (v) any changes in applicable laws or accounting rules following the date hereof; (vi) the public announcement or completion of the Transactions contemplated by this Agreement (provided that no such announcement shall be in violation of the terms hereof); (vii) any natural disaster or acts of God; (viii) any failure by the Company to meet any internal or published projections, forecasts or revenue or earnings predictions (provided that the underlying causes of such failure shall not be excluded); or (ix) any changes in the share price of the Company (provided that the underlying causes of such changes shall not be excluded); except in the case of (i), (ii), (iii), (iv), (v), (vii) or (ix) above to the extent these effects or changes do not have a disproportionate effect or change on the Company as compared to other Persons in the industries in which the Company operates.
	“Nominee”	The Tel Aviv Stock Exchange Nominee Company Ltd.
	“Ordinary Share”	An ordinary share, without a nominal value, of the Company.

 

    3

     

    

 

	“Person”	An individual, a limited liability company, a partnership, a joint venture, a corporation, a trust, an unincorporated organization, any other entity and any governmental entity or any department or agency thereof. 
	“PIPE Shares”	50% (fifty percent) of the  Bonus Shares, of which (i) one half (i.e., 25% of the Bonus Shares) shall be designated as “Initial PIPE Shares” and (ii) one half (i.e., 25% of the Bonus Shares) shall be designated as the “Milestone Shares”.
	“Transaction Documents”	This Agreement, the Exchange Agreement, the Support Agreements, the Registration Rights Agreement, the Escrow Agreement, the IP Undertaking and any and all other documents contemplated to be delivered or executed in connection therewith and the transactions contemplated hereby and thereby.

 

2. The
Transaction

 

2.1. General.
Upon the terms and subject to the conditions set forth herein, at the Closing (as defined below), the Investor shall purchase from
the Company, and the Company shall issue and sell to the Investor, the PIPE Shares in consideration for the Cash Consideration
(except that the Milestone Shares and the Milestone Cash Consideration shall be deposited with the Escrow Agent until the release
thereof in accordance with the terms of this Agreement and the Escrow Agreement).

 

2.2. Stock
Splits, Etc. In the event of any stock split, bonus shares, consolidation, share dividend (including any dividend or distribution
of securities convertible into share capital), reorganization, reclassification, combination, recapitalization or other like change
with respect to the Ordinary Shares occurring after the date hereof and prior to the Closing, all references in this Agreement
to numbers of Bonus Shares (including Milestone Shares) and all related calculations shall be equitably adjusted to the extent
necessary to provide to the Investor the same economic effect as contemplated by this Agreement.

 

2.3. Advance.
Notwithstanding anything to the contrary hereunder, (a) Investor undertakes to transfer (or cause to be transferred, including
through the Escrow Agent) to the Company’s Bank Account, as soon as promptly practicable following the date hereof, a cash sum
equal to US$500,000 (five hundred thousand US Dollars) (the “Advance”) on account of the Cash Consideration
(and, for the sake of clarity, the Initial Cash Consideration), and (b) if this Agreement is validly terminated in accordance with
Section 3.4 below, then (A) the Company shall immediately issue a number of Ordinary Shares equal to the quotient obtained by dividing
(A) the Advance expressed in NIS (based on the Exchange Rate as of the Business Day immediately prior to the date hereof) by (B)
the Agreed Advance PPS, with fractional shares rounded up to the nearest whole share; subject to adjustment in the case of split,
reclassification, dividends and the like as more fully detailed herein if occurs following the date hereof (the “Advance
Shares”) in the name of the Nominee (for the benefit of the Investor, to be deposited with the Investor’s securities
account) together with a copy of a letter of issuance (the “Letter of Issuance”) to the Nominee representing the
Advance Shares together with an instruction letter (the “Instruction Letter”) irrevocably instructing it to accredit
the securities account of the TASE member in which the Investor’s securities account is managed (the “Investor TASE
Member”), for the benefit of the Investor’s securities account therein, by the number of Advance Shares; (B) for
the sake of clarity, the Company shall obtain the approval of TASE for such issuance; (C) for the sake of clarity, despite Section
3.5 hereof, Sections 5, 6, 7, 10, 11.10 and 13 shall continue to be valid; and (D) if the Company is the one terminating this Agreement,
the issuance of the Advance Shares to the Investor within three (3) Business Day following termination shall be a condition precedent
to such termination.

 

    4

     

    

 

2.4. Guarantee.
It is hereby agreed that, notwithstanding anything to the contrary hereunder, “Cash Consideration” (including Initial
Cash Consideration and Milestone Cash Consideration), for all intents and purposes hereunder and under the other Transaction Documents,
may consist (and therefore, the definition of such terms shall include) of an executed bank guarantee or other similar instrument;
provided that Investor may not use such instrument (in lieu of cash) unless the form and substance thereof is acceptable
to Bonus.

 

3. Closing
Conditions; Termination Etc. 

 

3.1. Mutual
Closing Conditions. The obligations of each party to consummate the Transaction, including the issuance of the PIPE Shares
and the transfer of the Cash Consideration as contemplated herein, is subject to the satisfaction of all of the following conditions
precedent (the “Mutual Closing Conditions”):

 

3.1.1. The
approval of the TASE for the registration of all the Bonus Shares, including the Milestone Shares, has been duly obtained (the
“TASE Approval”). In this respect, the Company undertakes to take all action to register these securities for
trading on the TASE. All expenses incurred in connection with such registration will be borne by the Company.

 

3.1.2. No
governmental authority or court of competent jurisdiction shall have enacted, issued, promulgated, enforced or entered any statute,
rule, regulation, executive order, decree, judgement, injunction or other order (whether temporary, preliminary or permanent) which
(i) is in effect and (ii) has the effect of making the consummation of the Transaction illegal or otherwise prohibiting,
restraining, enjoining or preventing consummation thereof.

 

3.1.3. The
closing of the transactions contemplated by the Exchange Agreement shall have occurred.

 

3.2. Company
Closing Conditions. The obligations of the Company to consummate the Transaction is subject to the satisfaction (or waiver
in writing by the Company) of all of the following conditions precedent (the “Company Closing Conditions”):

 

3.2.1. The
representations and warranties of Investor set forth herein shall be true and correct in all material respects as of the date hereof
and as of the Closing Date, as if made at and as of such time (in each case, except to the extent expressly made as of an earlier
date, in which case as of such date).

 

3.2.2. Investor
shall have performed or complied in all material respects with all covenants and obligations required by this Agreement to be performed
or complied with by it on or prior to the Closing Date.

 

3.2.3. The
Investor shall have deposited the Cash Consideration (minus the Advance if previously transferred to the Company’s Bank
Account) with the Escrow Agent in accordance with the Escrow Agreement and this Agreement.

 

3.3. Investor
Closing Conditions. The obligations of the Investor to consummate the Transaction is subject to the satisfaction (or waiver
in writing by the Investor) of all of the following conditions precedent (the “Investor Closing Conditions” and
together with the Mutual Closing Conditions and the Company Closing Conditions, the “Closing Conditions”):

 

3.3.1. The
representations and warranties of the Company set forth herein shall be true and correct in all material respects as of the date
hereof and as of the Closing Date, as if made at and as of such time (in each case, except to the extent expressly made as of an
earlier date, in which case as of such date), except for those representations and warranties that are qualified by materiality
and except for those representations and warranties in Sections 5.1.1, 5.2 and 5.3, all of which shall be true and correct in all
respects.

 

    5

     

    

 

3.3.2. The
Company shall have performed or complied in all material respects with all covenants and obligations required by this Agreement
to be performed or complied with by it on or prior to the Closing Date.

 

3.3.3. All
of the documents to be delivered by the Company pursuant to Section 4 below shall be substantially in the form as attached to this
Agreement, or, if not attached, in a form and substance reasonably satisfactory to the Investor and shall be delivered to the Investor
at or prior to the Closing.

 

3.3.4. From
the date hereof until the Closing there will have been no Material Adverse Effect.

 

3.3.5. The
Company shall have executed and delivered to the Investor a registration rights agreement in the form attached hereto as Exhibit
D (the “Registration Rights Agreement”).

 

3.3.6. The
Support Agreements and IP Undertaking shall be valid and in full force and effect and not rescinded in any manner.

 

3.4. Termination.
This Agreement may be terminated at any time before the Closing as follows:

 

3.4.1. By
mutual written consent of the parties; or

 

3.4.2. In
the event that the Closing shall not occur on or before 5:00 p.m. (IL Time) on the 30th day following the date hereof
(the “Outside Time”), either party may terminate this Agreement by written notice to the other party; provided
that the party seeking to terminate this Agreement pursuant to this ‎Section shall not have breached in any material respect
its obligations under this Agreement in any manner that shall have caused the failure to consummate the Closing on or before such
date; or

 

3.4.3. In
the event that Wize shall have not either (i) deposited the Cash Consideration with the Escrow Agent (minus the Advance
if previously transferred to the Company’s Bank Account) or (ii) provided evidence that it has received the Cash Consideration
(whether in its own bank account or in an account administered by an escrow agent who may be the Escrow Agent), in each case, by
no later than January 20, 2020 at 5:00 p.m. (IL Time) (the “Confirmation Time”), either party may, within 24
hours thereafter, terminate this Agreement by written notice to the other party.

 

3.5  
Effect of Termination. Any termination of this Agreement under ‎Section 3.4 above will be effective immediately
upon written notice of the terminating party to the other parties hereto specifying the provision of this Agreement on which such
termination is based. If this Agreement is terminated as provided in ‎Section 3.4 this Agreement shall forthwith become
void and shall have no further effect, without any liability or obligation on the part of either party, except (i) other than
in the event of valid termination pursuant to Section 3.4.3 above - for claims for damages to the extent that such termination
results from a material and willful breach by a party of any of its representations, warranties, covenants or agreements in this
Agreement; and (ii) notwithstanding the foregoing, this Section 3.5 and ‎Section 13 shall survive any termination
of this Agreement in accordance with their respective terms.

 

    6

     

    

 

4. Closing.

 

4.1. Closing
Date. The closing of the sale and purchase of the Bonus Shares (the “Closing”) shall take place at 10:00 a.m.,
local time (Israel) electronically via the exchange of documents and signatures, within no later than the second (2nd) Business
Day immediately following the satisfaction (or wavier, by the party entitled to provide such waiver) of all the Closing Conditions
(other than those respective conditions that by their nature are to be satisfied only at the Closing), or such other date and time
as the Company and the Investor agree in writing (the date on which the Closing actually takes place, the “Closing Date”).

 

4.2. Closing
Deliverables. At the Closing, the following actions will take place, all of which shall be deemed to have occurred simultaneously
and no transaction shall be deemed to have been completed or any document delivered until all such transactions have been completed
and all required documents delivered:

 

4.2.1. The
Company will issue and allocate (i) the Initial Shares in the name of the Nominee (for the benefit of the Investor, to be deposited
with the Investor’s securities account) and (ii) the Milestone Shares in the name of the Nominee (for the benefit of the
Escrow Account managed by the Escrow Agent, to be deposited with the Escrow Agent’s securities account).

 

4.2.2. The
Company shall deliver to the Investor a certificate dated as of the Closing Date, duly signed on behalf of the Company by the Chief
Executive Officer of the Company, certifying that (i) the Board of Directors has approved the Transaction (and attaching a copy
of the resolutions) and (ii) the Investor Closing Conditions (other than those waived in writing by the Investor, if any) and the
Mutual Closing Conditions have been satisfied.

 

4.2.3. The
Company shall deliver to Investor a copy of the TASE Approval.

 

4.2.4. The
Company shall deliver to Investor a copy of a letter of issuance (the “Letter of Issuance”) to the Nominee representing
the Bonus Shares together with a an instruction letter (the “Instruction Letter”) irrevocably instructing it to
accredit (x) the securities account of the TASE member in which the Investor’s securities account is managed (the “Investor
TASE Member”), for the benefit of the Investor’s securities account therein, by the number of Initial Shares and
(y) the securities account of the TASE member in which the Escrow Agent’s securities account is managed (the “Agent
TASE Member”) for the benefit of the Escrow Agent’s securities account therein, by the number of Milestone Shares;

 

4.2.5. The
Company shall deliver to Investor a copy of the Company’s immediate report to be filed with respect to the issuance of the
Bonus Shares (the “Immediate Report”).

 

4.2.6 Within
one (1) Business Day after Closing, the Company shall file the Immediate Report with the Israeli Securities Authority (the “ISA”)
and shall provide the Investor with evidence of delivery to the Nominee of the Letter of Issuance and the Instruction Letter, and
any other documents necessary for listing the Bonus Shares with the TASE.

 

5. Representations
and Warranties of the Company

 

The Company hereby
represents, confirms and warrants to the Investor that the following representations are true, correct and complete as of the execution
date of this Agreement and as of the Closing, except as set forth in the Company Disclosure Letter delivered to the Investor on
the date hereof (such disclosures being considered to be made for purposes of the specific sub-Section of the Company Disclosure
Letter in which they are made and for purposes of all other Sections only to the extent the relevance of such disclosure is reasonably
apparent on its face):

 

5.1.
Organization and Qualification.

 

5.1.1. Each
of the Company and each of its “Subsidiaries” (which for purposes of this Agreement means any joint venture
or any entity in which the Company, directly or indirectly, owns any of the capital stock or holds an equity or similar interest)
are entities duly organized and validly existing and in good standing (excluding for purposes of the representation regarding good
standing, any Subsidiary formed in Israel) under the laws of the jurisdiction in which they are formed, and have the requisite
power and authorization to own their properties and to carry on their business as now being conducted and as presently proposed
to be conducted.

 

    7

     

    

 

5.1.2. Each
of the Company and each of its Subsidiaries is duly qualified as a foreign entity to do business and is in good standing in every
jurisdiction in which its ownership of property or the nature of the business conducted by it makes such qualification necessary,
except to the extent that the failure to be so qualified or be in good standing would not reasonably be expected to have a Material
Adverse Effect.

 

5.2. Authorization;
Enforcement; Validity. The Company has the requisite corporate power and authority to enter into and perform its obligations
under this Agreement, and each of the Transaction Documents and, subject to the TASE Approval, to issue the Bonus Shares, including
the Milestone Shares, in accordance with the terms hereof and thereof. The execution and delivery of this Agreement and the other
Transaction Documents by the Company and the consummation by the Company of the transactions contemplated hereby and thereby, including
the issuance of the Bonus Shares, have been duly authorized by the Company’s Board of Directors and no further consent or
authorization is required from the Company, its Board of Directors or its shareholders. This Agreement and the other Transaction
Documents have been duly executed and delivered by the Company, and constitute the legal, valid and binding obligations of the
Company, enforceable against the Company in accordance with their respective terms, except as such enforceability may be limited
by general principles of equity or applicable bankruptcy, insolvency, reorganization, moratorium, liquidation or similar laws relating
to, or affecting generally, the enforcement of applicable creditors’ rights and remedies (the “Bankruptcy and Equity
Exceptions”).

 

5.3. Issuance
of Securities. The issuance of the Bonus Shares (including the Milestone Shares) is duly authorized and, upon issuance in accordance
with the terms of the Transaction Documents, such Bonus Shares shall be validly issued and free from all preemptive or similar
rights, taxes, liens, charges and other encumbrances (other than lock-up provisions under applicable securities laws) with respect
to the issue thereof and the Bonus Shares shall be fully paid and nonassessable. As of the Closing, a number of Ordinary Shares
shall have been duly authorized and reserved for issuance which equals or exceeds (the “Required Reserved Amount”)
the sum of the maximum number of Bonus Shares issuable hereunder. As of the date hereof, there are 2,158,532,878 Ordinary Shares
authorized and unissued. As of the Closing Date, the Initial Shares and the Milestone Shares (on as if issued basis) shall represent
the percentages of the outstanding share capital of the Company as set forth in Section 5.3 of the Company Disclosure Letter, respectively.
For the sake of clarity, at the Milestone Closing, the Milestone Shares to be released to Investor will be validly issued, fully
paid and nonassessable and free from all preemptive or similar rights, taxes, liens, charges and other encumbrances (other than
lock up provisions under applicable securities laws). The offer and issuance by the Company of the Bonus Shares is exempt from
the need to publish a prospectus in accordance with the ISL.

 

5.4. No
Conflicts. The execution, delivery and performance of the Transaction Documents by the Company and the consummation by the
Company of the transactions contemplated hereby and thereby (including the issuance of the Initial Shares and the Milestone Shares)
will not (i) result in a violation of the Articles of Association of the Company, any memorandum of association, certificate of
incorporation, certificate of formation, bylaws, any certificate of designations or other constituent documents of the Company
or any of its Subsidiaries, any capital stock of the Company or any of its Subsidiaries or the articles of association or bylaws
of the Company or any of its Subsidiaries or (ii) conflict with, or constitute a default (or an event which with notice or lapse
of time or both would become a default) in any respect under, or give to others any rights of termination, amendment, acceleration,
anti-dilution. or cancellation of, any agreement, indenture or instrument to which the Company or any of its Subsidiaries is a
party, or (iii) result in a violation of any law, rule, regulation, order, judgment or decree applicable to the Company or any
of its Subsidiaries or by which any property or asset of the Company or any of its Subsidiaries is bound or affected. The Company
has obtained all consents and authorizations that shall be necessary or required lawfully for its execution, delivery and performance
of this Agreement and the other Transaction Documents (including the issuance of the Bonus Shares), except for receipt of the
TASE Approval. 

 

    8

     

    

 

5.5. ISA
Documents; Financial Statements. Since January 1, 2018, the Company has timely filed all reports, schedules, forms, statements
and other documents required to be filed by it with the ISA pursuant to the reporting requirements of the ISL (all of the foregoing
filed prior to the date hereof or prior to the Closing Date, and all exhibits included therein and financial statements, notes
and schedules thereto being hereinafter referred to as the “ISA Documents”). As of their respective filing dates,
the ISA Documents complied in all material respects with the requirements of applicable law, including the ISL, applicable to the
ISA Documents, and none of the ISA Documents, at the time they were filed with the ISA, contained any untrue statement of a material
fact or omitted to state a material fact required to be stated therein or necessary in order to make the statements therein, in
the light of the circumstances under which they were made, not misleading. As of their respective filing dates, the financial statements
of the Company included in the ISA Documents complied as to form in all material respects with applicable accounting requirements
and the published rules and regulations of the ISA with respect thereto as in effect as of the time of filing. Such financial statements
have been prepared in accordance with IFRS, consistently applied, during the periods involved (except (i) as may be otherwise indicated
in such financial statements or the notes thereto, or (ii) in the case of unaudited interim statements, to the extent they may
exclude footnotes or may be condensed or summary statements) and fairly present in all material respects the financial position
of the Company and its Subsidiaries as of the dates thereof and the results of its operations and cash flows for the periods then
ended (subject, in the case of unaudited statements, to normal year-end audit adjustments which will not be material either individually
or in the aggregate).

 

5.6. Absence
of Certain Changes. Since September 30, 2019, there has been no Material Adverse Effect. Since September 30, 2019, neither
the Company nor any of its Subsidiaries has (i) declared or paid any dividends, (ii) sold any assets, individually or in the aggregate,
outside of the ordinary course of business or (iii) had capital expenditures, outside the ordinary course of business.

 

5.7. TASE
Listing. The Ordinary Shares are listed on the TASE. No order ceasing, halting or suspending
trading in the Ordinary Shares or prohibiting the sale of the Ordinary Shares is outstanding against the Company, and, to the best
of the Company’s knowledge, no investigations or proceedings for such purposes are pending or threatened. The Company
has not received notice (written or oral) from the TASE to the effect that the Company
is not in compliance with the listing or maintenance requirements of the TASE.

 

5.8. No
Undisclosed Events, Liabilities, Developments or Circumstances. As of the date hereof, other than the Transactions, no event,
liability, development or circumstance has occurred or exists, or is contemplated to occur, that would be required to be disclosed
by the Company under applicable securities laws, which has not been publicly announced. The total amount of the debts or trade
payables to the Company’s directors and officers that are outstanding as of November 30, 2019 (the “Outstanding
Management Fees”) is, approximately, as set forth in Section 5.8 of the Company Disclosure Letter.

 

    9

     

    

 

5.9. Equity
Capitalization. As of the date hereof, the authorized capital stock of the Company consists of 3,000,000,000 Ordinary Shares,
of which, as of the date hereof, 841,467,122 Ordinary Shares are issued and outstanding, 80,000,000 Ordinary Shares are reserved
for issuance pursuant to the Company’s stock option plans and 2,078,532,878 Ordinary Shares are reserved for issuance pursuant
to securities (other than the aforementioned options and the Bonus Shares) exercisable or exchangeable for, or convertible into,
Ordinary Shares. All of such outstanding shares have been, or upon issuance will be, validly issued and are fully paid and nonassessable.
None of the Company’s capital stock is subject to preemptive rights, charges, pledges, security interest, right of first
refusal, or any other similar rights or any liens or encumbrances suffered or permitted by the Company. Except as disclosed in
an applicable subsection of Section 5.9 of the Company Disclosure Letter, (i) there are no outstanding options, warrants,
scrip, rights to subscribe to, calls or commitments of any character whatsoever relating to, or securities or rights convertible
into, or exercisable or exchangeable for, any shares of capital stock of the Company or any of its Subsidiaries, or contracts,
commitments, understandings or arrangements by which the Company or any of its Subsidiaries is or may become bound to issue additional
shares of capital stock of the Company or any of its Subsidiaries or options, warrants, scrip, rights to subscribe to, calls or
commitments of any character whatsoever relating to, or securities or rights convertible into, or exercisable or exchangeable for,
any shares of capital stock of the Company or any of its Subsidiaries; (ii)  there are no outstanding debt securities, notes,
credit agreements, credit facilities or other agreements, documents or instruments evidencing borrowed funds of the Company or
any of its Subsidiaries or by which the Company or any of its Subsidiaries is or may become bound exceeding $US100,000 in the aggregate;
(iii) there are no agreements or arrangements under which the Company or any of its Subsidiaries is obligated to register
the sale of any of their securities; (iv)  there are no outstanding securities or instruments of the Company or any of its
Subsidiaries which contain any redemption or similar provisions, and there are no contracts, commitments, understandings or arrangements
by which the Company or any of its Subsidiaries is or may become bound to redeem a security of the Company or any of its Subsidiaries;
(v) there are no securities or instruments containing anti-dilution or similar provisions and to the extent the Company does
have securities or instruments with such provisions, none of which will be triggered by the issuance of the Bonus Shares, including
the Milestone Shares; (vi)  neither the Company nor any Subsidiary has any stock appreciation rights or “phantom stock”
plans or agreements or any similar plan or agreement; and (vii) the Company and its Subsidiaries have no liabilities or obligations
required to be disclosed in the ISA Documents but not so disclosed in the ISA Documents. The Company has furnished or made available
to the Investors true, correct and complete copies of the Company’s Articles of Association, as amended and as in effect
on the date hereof (the “Articles of Association”), and the Company’s Memorandum of Association, if applicable,
as amended and as in effect on the date hereof.

 

5.10. Conduct
of Business; Regulatory Permits. Neither the Company nor any of its Subsidiaries is in violation of any term of or in default
under any material provision of its Articles of Association or Memorandum of Association or their organizational charter or memorandum
of association or certificate of incorporation or articles of association or bylaws, respectively. Neither the Company nor any
of its Subsidiaries is in violation of any judgment, decree or order or any statute, ordinance, rule or regulation applicable to
the Company or any of its Subsidiaries, except for possible violations which would not, individually or in the aggregate, reasonably
be expected to have a Material Adverse Effect. Without limiting the generality of the foregoing, the Company is in compliance,
in all material respects, with the rules, regulations and requirements of the ISA and TASE and has no knowledge of any facts or
circumstances that would reasonably lead to delisting or suspension of the Ordinary Shares by the TASE in the foreseeable future.

 

    10

     

    

 

5.11. Absence
of Litigation. Except as set forth in the ISA Documents, there is no action, suit, or proceeding before or by any court, public
board, government agency, self-regulatory organization or body, including ISA and TASE, pending or, to the knowledge of the Company,
threatened against or affecting the Company or any of its Subsidiaries, the Ordinary Shares or any of the Company’s Subsidiaries
or any of the Company’s or its Subsidiaries’ officers or directors, whether of a civil or criminal nature or otherwise,
in their capacities as such, except for actions, suits or proceedings which would not, individually or in the aggregate, reasonably
be expected to have a material impact on the Company.

 

5.12. Intellectual
Property Rights. The Company and its Subsidiaries own or possess rights or licenses to use all trademarks, trade names, service
marks, service mark registrations, service names, original works of authorship, patents, patent rights, copyrights, inventions,
licenses, approvals, governmental authorizations, trade secrets and other intellectual property rights and all applications and
registrations therefor (together, “Intellectual Property Rights”) that are materially necessary to conduct
their respective businesses. None of the Company’s or its Subsidiaries’ Intellectual Property Rights have expired
or terminated or have been abandoned or are expected to expire or terminate or are expected to be abandoned, within three years
from the date of this Agreement. The Company does not have any knowledge of any infringement by the Company or any of its Subsidiaries
of Intellectual Property Rights of others. There is no claim, action or proceeding being made or brought, or to the knowledge
of the Company or any of its Subsidiaries, being threatened, against the Company or any of its Subsidiaries regarding its Intellectual
Property Rights. Neither the Company nor any of its Subsidiaries is aware of any facts or circumstances which might give rise
to any of the foregoing infringements or claims, actions or proceedings. The Company and its Subsidiaries have taken reasonable
security measures to protect the secrecy, confidentiality and value of all of their Intellectual Property Rights. All of the Company’s
and its Subsidiaries’ employees who were or are engaged in the creation, development, modification, improvement or invention
of any material Intellectual Property Rights by or on behalf of the Company or any of its Subsidiaries have entered into written
agreements with the Company or one of its Subsidiaries assigning to the Company or any of its Subsidiaries, as applicable, all
rights, title and interests in and to any such Intellectual Property arising out of such Person’s employment by, engagement
by, or Contract with the Company or any of its Subsidiaries.

 

5.13. Insurance.
The Company and each of its Subsidiaries are insured by insurers of recognized financial responsibility against such losses and
risks and in such amounts as management of the Company believes to be prudent and customary in the businesses in which the Company
and its Subsidiaries are engaged. Neither the Company nor any such Subsidiary has been refused any insurance coverage sought or
applied for and neither the Company nor any such Subsidiary has any reason to believe that it will not be able to renew its existing
insurance coverage as and when such coverage expires or to obtain similar coverage from similar insurers as may be necessary to
continue its business.

 

5.14. Brokers;
Fees and Expenses. Except as contemplated by Section 6.7 and 10 hereof, there is no investment banker, broker, finder or similar
agent or other Person that has been retained by or is authorized to act on behalf of the Company or any of its Subsidiaries who
is entitled to any financial advisor, brokerage, finder or other similar fee or commission in connection with the transactions
contemplated hereby.

 

5.15. No
Other Representations or Warranties. Except for the representations and warranties contained in this Section 5 and in any certificate
delivered by the Company hereunder, neither the Company nor any other Person on behalf of the Company or its Subsidiaries makes
any other express or implied representation or warranty with respect to the Company or its Subsidiaries or with respect to any
other information provided by or on behalf of the Company or its Subsidiaries.

 

    11

     

    

 

6. Representations
and Warranties of the Investor 

 

The Investor hereby
represents, confirms and warrants to the Company that the following representations shall be true, correct and complete as of the
execution date of this Agreement and as of the Closing, except as set forth in the Wize Disclosure Letter delivered to the Company
on the date hereof (such disclosures being considered to be made for purposes of the specific sub-Section of the Wize Disclosure
Letter in which they are made and for purposes of all other Sections only to the extent the relevance of such disclosure is reasonably
apparent on its face):

 

6.1. Organization
and Qualification. The Investor is a corporation duly organized and validly existing and in good standing under the laws of
the State of Delaware, and has the requisite power and authorization to own its properties and to carry on its business as now
being conducted and as presently proposed to be conducted.

 

6.2. Authorization;
Enforcement; Validity. The Investor has the requisite corporate power and authority to enter into and perform its obligations
under this Agreement, and each of the Transaction Documents in accordance with the terms hereof and thereof, including remittance
of the Cash Consideration. The execution and delivery of this Agreement and the other Transaction Documents by the Investor and
the consummation by the Investor of the transactions contemplated hereby and thereby, have been duly authorized by the Investor’s
Board of Directors and no further consent or authorization is required by the Investor, its Board of Directors or its shareholders.
This Agreement and the other Transaction Documents have been duly executed and delivered by the Investor, and constitute the legal,
valid and binding obligations of the Investor, enforceable against the Investor in accordance with their respective terms, except
as such enforceability may be limited by the Bankruptcy and Equity Exceptions.

 

6.3. Sufficient
Funds. The Investor will have prior to the Closing, pursuant to financing agreement entered into on or prior to the date hereof,
sufficient funds to consummate the transactions contemplated hereunder.

 

6.4. No
Arrangements. Except as otherwise provided herein, there are no agreements or other voting arrangements, oral or written, among
the Investor and any other Person who is known to the Investor to be an existing shareholder of the Company with respect to the
Company.

 

6.5. Experience.
Without derogating from the representations and warranties made by the Company, the Investor represents that it has made its own
assessment of the present condition and the future prospects of the Company and is sufficiently experienced to make an informed
judgment with respect thereto.

 

6.6. Acquisition
for Own Account. The Investor is acquiring the Bonus Shares as principal for its own account for investment purposes only and
not with an immediate view to or for distributing or reselling such Bonus Shares or any part thereof, without prejudice, however,
to the Investor’s right at all times to sell or otherwise dispose of all or any part of such Bonus Shares in compliance with applicable
securities laws, including lock up provisions prescribed by applicable laws and regulations.

 

6.7. Brokers;
Fees and Expenses. Except for H.C. Wainwright & Co., LLC (“HCW”), a true and complete copy of which
engagement letter has been made available to the Company (the “HCW Letter”), there is no investment banker,
broker, finder or similar agent or other Person that has been retained by or is authorized to act on behalf of Investor or any
of its Subsidiaries who is entitled to any financial advisor, brokerage, finder or other similar fee or commission in connection
with the transactions contemplated hereby.

 

    12

     

    

 

6.8. No
Other Representations or Warranties. Except for the representations and warranties contained in this Section 6 and in any certificate
delivered by the Investor hereunder, neither the Investor nor any other Person on behalf of Investor or its Subsidiaries makes
any other express or implied representation or warranty with respect to the Investor or its Subsidiaries or with respect to any
other information provided by or on behalf of the Investor or its Subsidiaries.

 

7. Resale;
Lock-Up

 

The Investor hereby
undertakes, vis-à-vis the Company, not to sell any portion of the Bonus Shares, to the extent that such sale would be prohibited
by Section 15C of the ISL on the resale of the Bonus Shares.

 

8. 
Additional Issuance of Securities

 

8.1. Without
derogating from Section 11.5 hereof, if the Company conducts, at any time and from time to time, from the date hereof until the
earlier of (i) nine (9) months following the Closing Date, and (ii) the valid termination of this Agreement (the “Restricted
Period”), a Subsequent Financing (including entering into an agreement contemplating a Subsequent Financing during the
Restricted Period where consummation thereof will occur following such period) in which the effective price per Ordinary Share
is lower than NIS 0.30 (thirty Agorot of NIS) (the “Reduced PPS”), then (A) the Agreed PPS hereunder shall,
for all intents and purposes be reduced to be equal to the Reduced PPS and the number of Bonus Shares shall be equal to the number
obtained by dividing the Agreed Amount by the Reduced PPS (and consequently, the number of Initial Shares and Milestone Shares
shall be correspondingly increased), and (B) the Investor shall be issued, concurrently with the Subsequent Financing, a number
of Ordinary Shares equal to (x) the number of Initial Shares (as so adjusted) less the number of Initial Shares already
issued at Closing (which shares shall be delivered to Investor) and (y) the number of Milestone Shares (as so adjusted) less
the number of Milestone Shares already issued (which shares shall be delivered to Investor or, if the Milestone Closing shall
have not occurred by such time, to the Escrow Agent); provided however that if, as a result of the aforesaid adjustments,
the number of Bonus Shares issuable to the Investor hereunder (such number, the “Total Issuance Number”) shall
exceed, in the aggregate, 19.99% of the outstanding Ordinary Shares of the Company as of the Closing (the “Maximum Issuance
Number”), then the Company shall not consummate the Subsequent Financing unless and until it validly obtains shareholder
approval and approval of TASE for the issuance of the Ordinary Shares to Investor hereunder.

 

8.2. Notwithstanding
the foregoing, Section 8.1 shall not apply to a Subsequent Financing where the issuance of Equity Security is as follows:
(a) the issuance of Equity Securities to consultants, employees, officers or directors of the Company pursuant to any stock or
option plan duly adopted by the Company; (b) upon exercise or conversion of any Ordinary Shares Equivalents outstanding as of the
date hereof; provided that the terms of such Ordinary Shares Equivalents or agreements are not amended, modified or changed on
or after the date hereof, without the Investor’s prior written consent; (c) any Equity Securities issued pursuant to any equipment
leasing arrangement or debt financing from a bank or similar financial institution whose primary business is lending money and
not investing in securities; (d) Equity Securities issued to a Strategic Partner but which Equity Securities do not represent,
in the aggregate, more than one percent (1%) of the issued and outstanding share capital of the Company, without the Investor’s
prior written consent; (e) Equity Securities issued in conjunction with any stock split, stock dividend or recapitalization of
the Company; or (f) any securities issuable under this Agreement or the other Transaction Documents.

 

8.3. If
the Company, at any time and from time to time following the date hereof, issues any Ordinary Shares or Ordinary Shares Equivalents,
or pays any amounts, as a result of the matters set forth in Exhibit E hereto, then the Company shall compensate
the Investor in the manner set forth in Exhibit E.

 

    13

     

    

 

8.4. 
“Equity Securities” means Ordinary Shares or Ordinary Shares Equivalents. “Ordinary Shares
Equivalents” means Ordinary Shares and any other securities of the Company which would entitle the holder thereof to
acquire at any time Ordinary Shares, including any debt, preferred stock, rights, options, warrants or other instrument (including
American Depositary Shares) that is at any time convertible into or exchangeable for, or otherwise entitles the holder thereof
to receive, Ordinary Shares. A “Subsequent Financing” means the offer, issuance, sale, grant, or otherwise dispose
of any of the Equity Securities. A “Strategic Partner” means an entity which is in the pharmaceutical industry
and has the potential to improve the commercialization of the Company’s products in addition to the investment of funds in the
Company, but shall not include an entity where the Company is issuing securities for the primary purpose of raising capital.

 

9. Nasdaq
Uplisting.

 

9.1. The
Company shall make reasonable commercial efforts to either (i) implement a Level 2 American Depository Receipt (“ADR”)
program (the “ADR Program”) including the listing of American Depositary Shares representing Ordinary Shares
of the Company on the Nasdaq Capital Market or (ii) to list the Company’s Ordinary Shares for trading on the Nasdaq Capital
Market (each of these two, individually: the “Nasdaq Listing”), in each case, as soon as practicable and in
any case not later than 180 days following the date of the Closing (the “Initial Deadline”).

 

9.2. If,
for any reason, the Nasdaq Listing does not occur until the Initial Deadline, the Investor shall be entitled, in addition to any
other rights it may have hereunder or under applicable law, that the Company shall pay to the Investor an amount, as liquidated
damages and not as a penalty, equal to (i) one eighth percent (0.125%) of the Agreed Amount, for the first 30 days of delay beyond
the Initial Deadline, (ii) for the 30 days of delay thereafter, one eighth percent (0.125%) of the Agreed Amount, (iii) for the
30 days of delay thereafter, one quarter percent (0.25%) of the Agreed Amount, and (iv) for each 30 days of delay thereafter, one
percent (1%) of the Agreed Amount. The liquidated damages pursuant to the terms hereof shall apply on a daily pro-rata basis for
any portion of a 30-day period prior to the Nasdaq Listing and be paid on the earlier of (i) the Nasdaq Listing (if occurs after
the Initial Deadline) and (ii) twelve months following the Closing. If the Company fails to timely pay any liquidated damages pursuant
to this Section in full, such delayed payments shall bear interest beginning on the first (1st) day following the due
date thereof, calculated at the annual rate of two percent (2.0%) over the prime interest rate quoted by the Wall Street Journal
on the date such payment is due, compounded monthly; provided, however, that in no event shall such annual interest rate exceed
the maximum rate allowed under applicable law.

 

9.3. The
payment of liquidated damages shall be, at the Company’s discretion, in either cash (in $US) or Ordinary Shares. In case the payment
is in Ordinary Shares, (A) the number of which shall be determined by dividing (x) the amount of liquidated damages, together with
any default interest accrued thereon (as such sum is converted into $US per the Exchange Rate on the date immediately prior to
the issuance) payable by (y) the average closing price of such shares on TASE during a 30 trading days prior to the issuance date
and (B) such Ordinary Shares shall be validly issued, fully paid and nonassessable and free from all preemptive or similar rights,
taxes, liens, charges and other encumbrances.

 

9.4. The
Company undertakes that, if the Nasdaq Listing entails the ADR Program (i.e., clause (i) of Section 9.1), at Investor’s election,
the Bonus Shares (or any part thereof) held by the Investor shall be converted into American Depositary Shares, at the Company’s
expense, at any time following the completion of the Nasdaq Listing (as contemplated herein).

 

    14

     

    

 

9.5. It
is hereby clarified that (i) the Nasdaq Listing (as defined in Section 9.1 hereof) shall not be deemed completed unless the Company’s
registration statement on Form 20-F filed with the SEC (the “Bonus Registration Statement”) has been declared
effective by the SEC and (ii) if the Nasdaq Listing entails implementation of the ADR Program, it shall be deemed completed only
when both the Bonus Registration Statement and the Company’s registration statement (filed by the depositary of the ADR Program)
on Form F-6 (the “Bonus Form F-6”) are declared effective by the SEC.

 

10. Taxes
and Expenses. Each party shall bear its own expenses in connection with the transactions contemplated hereunder; provided
however, that, subject to the consummation of the Closing, the Company shall, promptly thereafter and, in any event, not more
than one (1) Business Day following the Closing, pay the Investor (or directly to HCW) a sum equal to (i) one half (50%) of the
fees and expenses of HCW payable by the Investor for the Transaction, including with respect to the Exchange Agreement, in accordance
with the invoice issued to Investor pursuant to the HCW Letter less (ii) US$15,000 (together, the “Banker’s Fees”
and the - portion payable by the Company, the “Bonus Banker’s Fees”); provided further however
that the Company shall not be required to bear any part of the Banker’s Fees attributed to that portion of the proceeds raised,
if any, by the Investor in excess of the Cash Consideration.

 

11. Other
Covenants 

 

11.1. The
Company undertakes to publish and file with the ISA, as soon as practicable following the date hereof, a private placement report
as required by the provisions of the ISL.

 

11.2. The
Company undertakes to (a) file with the TASE, as soon as practicable following the date hereof an application for the TASE Approval
and (b) pay the TASE all fees required with respect to the registration of the Bonus Shares for trading.

 

11.3. The
Company shall make all other necessary filings and take all other necessary actions, in each case, in a timely manner and as required
by the ISL and the TASE to consummate the transactions contemplated by this Agreement.

 

11.4. The
Company shall provide the Investor drafts of the documentation set forth in Sections 11.1, 11.2 and 11.3 for Investor’s review
and comments.

 

11.5. The
Company undertakes that from the date of this Agreement and until the earlier of the Closing Date and the valid termination of
this Agreement (the “Pre-Closing Period”), it shall not, without the Investor’s prior written consent, (a) pay
any dividend or make any distribution in respect of the issued and outstanding shares of the Company, (b) issue any Ordinary Share
Equivalents for an effective price per Ordinary Share that is lower than the Agreed PPS (except for (i) issuance of shares upon
exercise of any options, warrants, rights or other Ordinary Share Equivalents outstanding on the date of this Agreement to the
extent they are set forth in Section 5.9 of the Company Disclosure Letter, (ii) the grant of stock options in the ordinary course
of business to employees who are not office holders and (iii) issuance of any securities issuable under this Agreement or the other
Transaction Documents), or (c) incur additional indebtedness that is senior in rank to the Advance or is otherwise secured.

 

    15

     

    

 

11.6. Each
of the parties hereto shall promptly do, make, execute or deliver, or cause to be done, made, executed or delivered, all such further
acts, documents and things as the other parties hereto may reasonably require from time to time for the purpose of giving effect
to this Agreement and the Transaction Documents and shall use reasonable commercial efforts and take all such steps as may be within
its power to cause the Closing Conditions (and, once applicable, the Milestone Closing Conditions) to be satisfied and otherwise
implement to their full extent the provisions of this Agreement and the Transaction Documents.

 

11.7. Recognizing
that, prior to the date hereof, the Company has received an oral opinion from BDO Israel (the “Appraiser”) with
respect to the fair market value of the Right to LO2A Proceeds (as defined under the Exchange Agreement), and that the Company
desires to obtain a more detailed written opinion to that effect from the Appraiser (the “Appraisal Report”)
as soon as practicable following the date hereof, Investor undertakes to supply all information reasonably required by the Appraiser
to issue the Appraisal Report; it being understood that (i) receipt of the Appraisal Report shall not be a Closing Condition of
either party, and (ii) without derogating from Investor’s representations and warranties in this Agreement or the Exchange
Agreement, Investor shall not have any responsibility or liability with respect to the Appraiser Report.

 

11.8. The
Company undertakes to use its reasonable commercial efforts to collaborate and engage appropriate U.S.-based senior management
team and scientific experts in the field of the Company’s business.

 

11.9. The
Company undertakes that it shall not, directly or indirectly, until (i) the earlier of (A) Closing and (B) the issuance of the
Advance Shares to Investor in accordance with this Agreement, pay any of the Outstanding Management Fees and (ii) the Nasdaq Listing,
pay any of the Outstanding Management Fees, other than, in the case of this clause (ii), in the aggregate, up to NIS 1,500,000
plus VAT.

 

11.10. The
Company shall, no later than one (1) Business Day following the Closing Date, file a public report with the ISA, disclosing the
Closing shall have occurred and disclosing any other material non-public information (if any) provided or made available to Investor
(or any of its agents or representatives) on or prior to the filing of the Closing Filing. Notwithstanding any affirmative disclosure
obligations of the Company pursuant to the terms of this Agreement or anything else to the contrary contained herein or therein,
(a) subject to clause (b) below, each of the Company shall not, and shall cause each of its officers, directors, employees and
agents to not on behalf of the Company, provide Investor with any material non-public information with respect to the Company from
and after the filing of the Closing Filing without the express prior written consent of the Investor, and (b) in the event that
the Company believes that a notice or communication to Investor contains material, nonpublic information with respect to the Company,
the Company shall so indicate to Investor prior to the delivery of such notice or communication, and such indication shall provide
Investor the means to refuse to receive such notice or communication.  In the absence of any such indication by the Company
to Investor, Investor shall be allowed to presume (and rely on the Company) that all matters relating to such notice or communication
do not constitute material nonpublic information with respect to the Company.

 

11.11. During
the Pre-Closing Period, (i) the Company shall notify the Investor promptly following becoming aware of (A) any inaccuracy in or
breach of any of its representations, warranties or covenants contained in this Agreement which would reasonably be expected to
cause any of the Mutual Closing Conditions or Investor Closing Conditions not to be timely (or at all) satisfied and (B) any other
event, condition, fact or circumstance that would make the timely satisfaction of any of the Mutual Closing Conditions or Investor
Closing Conditions impossible or unlikely; and (ii) the Investor shall notify the Company promptly following becoming aware of
(A) any inaccuracy in or breach of any of its representations, warranties or covenants contained in this Agreement which would
reasonably be expected to cause any of the Mutual Closing Conditions or Company Closing Conditions not to be timely (or at all)
satisfied and (B) any other event, condition, fact or circumstance that would make the timely satisfaction of any of the Mutual
Closing Conditions or Company Closing Conditions impossible or unlikely.

 

    16

     

    

 

11.12. If
any event, condition, fact or circumstance that is required to be disclosed pursuant to Section 11.11 requires any change in the
Company Disclosure Letter or the Wize Disclosure Letter, as applicable, or if any such event, condition, fact or circumstance would
require such a change assuming the Company Disclosure Letter or the Wize Disclosure Letter, as applicable, was dated as of the
date of the occurrence, existence or discovery of such event, condition, fact or circumstance, then the Company or Investor, as
applicable, may (but are not obligated to) deliver to the other party a written update to the Company Disclosure Letter or the
Wize Disclosure Letter, as applicable, specifying such change. In this respect, it is hereby agreed that (a) no such notice or
update shall be deemed to supplement or amend the Company Disclosure Letter, or the Wize Disclosure Letter, as applicable, for
the purpose of determining whether any of the Closing Conditions has been satisfied and (b) such notice or update shall be deemed
to supplement or amend the Company Disclosure Letter, or the Wize Disclosure Letter, as applicable, for the purpose of determining
the accuracy of any of the representations and warranties made by the Company or Investor in this Agreement (including for purpose
of any remedy for a breach thereof hereunder), only if (i) such notice or update is with respect to factual updates of the Company
Disclosure Letter or the Wize Disclosure Letter, as applicable, regarding events that occurred following the date hereof and (ii)
despite receipt of such notice, the Company or the Investor, as the case may be, determined to proceed with the Closing.

 

11.13. For
the sake of clarity, the Company undertakes that any distributions (in cash or in kind, including bonus shares) made with respect
to the Milestone Shares shall be made, until the Milestone Closing Date, to the Escrow Account (as defined in the Escrow Agreement).

 

12. Milestone
Closing

 

12.1. Milestone
Closing Date. The closing of the release from the Escrow Account of (i) the Milestone Shares to Investor and (ii) the Milestone
Cash Consideration to the Company (the “Milestone Closing”) shall take place at 10:00 a.m., local time (Israel)
electronically via the exchange of documents and signatures, within no later than the first (1st) Business Day immediately
following the satisfaction (or wavier, by the party entitled to provide such waiver) of all the Milestone Closing Conditions (other
than those respective conditions that by their nature are to be satisfied only at the Milestone Closing), or such other date and
time as the Company and the Investor agree in writing (the date on which the Milestone Closing actually takes place, the “Milestone
Closing Date”).

 

12.2. Milestone
Closing Deliverables. At the Milestone Closing, the following actions will take place, all of which shall be deemed to have
occurred simultaneously and no transaction shall be deemed to have been completed or any document delivered until all such transactions
have been completed and all required documents delivered:

 

12.2.1. The
Company shall deliver to the Investor a certificate dated as of the Milestone Closing Date, duly signed on behalf of the Company
by the Chairman of the Board of Directors and Chief Executive Officer of the Company, certifying that the Investor Milestone Closing
Conditions (other than those waived in writing by the Investor, if any) and the Milestone Mutual Closing Conditions have been satisfied.

 

    17

     

    

 

12.2.2. The
Company shall deliver to Investor a copy of the Company’s immediate report to be filed with respect to the occurrence of
the Milestone Closing (the “Milestone Immediate Report”).

 

12.2.3. Within
one (1) Business Day after the Milestone Closing, the Company shall file the Milestone Immediate Report with the ISA and shall
provide the Investor and any other documents necessary for listing the Milestone Shares with the TASE.

 

12.3. Milestone
Closing Conditions.

 

12.3.1. The
obligations of each party to consummate the Milestone Closing, including the release from the Escrow Account of (i) the Milestone
Shares to Investor and (ii) the Milestone Cash Consideration to the Company, is subject to the satisfaction of the following conditions
precedent (the “Milestone Mutual Closing Conditions”): no governmental authority or court of competent jurisdiction
shall have enacted, issued, promulgated, enforced or entered any statute, rule, regulation, executive order, decree, judgement,
injunction or other order (whether temporary, preliminary or permanent) which (i) is in effect and (ii) has the effect
of making the consummation of the Milestone Closing illegal or otherwise prohibiting, restraining, enjoining or preventing consummation
thereof.

 

12.3.2. The
obligations of the Company to consummate the Milestone Closing is subject to the satisfaction (or waiver in writing by the Company)
of the following condition precedent (the “Milestone Company Closing Conditions”): The Investor shall have delivered
to the Escrow Agent a letter confirming that the Milestone Closing shall have occurred.

 

12.3.3. The
obligations of the Investor to consummate the Milestone Closing is subject to the satisfaction (or waiver in writing by the Investor)
of all of the following conditions precedent (the “Milestone Investor Closing Conditions” and together with the
Milestone Mutual Closing Conditions and the Milestone Company Closing Conditions, the “Milestone Closing Conditions”):
(i) all of the documents to be delivered by the Company pursuant to Section 12.2 above shall be in a form as attached to this Agreement,
or, if not attached, in a form and substance reasonably satisfactory to the Investor and shall be delivered to the Investor at
or prior to the Milestone Closing; (ii) the Company shall have received (and delivered a copy thereof to Investor) an executed
letter from Nasdaq that approves the listing of the Ordinary Shares (or, if an ADR Program is to be implemented by the Company,
the American Depositary Shares representing such Ordinary Shares (“ADSs”) on the Nasdaq Capital Market (or other
superior tier of the Nasdaq market) (the “Nasdaq Approval”), or, if such Nasdaq Approval is conditioned, the
sole condition imposed and remaining unmet is meeting the minimum stockholders’ equity requirement under the applicable Nasdaq
Initial Listing Rules, which minimum stockholders’ equity requirement may be satisfied (as acknowledged by Nasdaq in such
letter) automatically solely by release of the Milestone Cash Consideration from the Escrow Account to the Company; (iii) the SEC
had no further comments to the Bonus Registration Statement and no updates thereto are necessary in order to comply with applicable
SEC rules relating thereto; (iv) if the Company determined to effect the Nasdaq Listing through an ADR Program, the Bonus Form
F-6 has been filed with the SEC with a request of effectiveness thereof automatically upon the effectiveness of the Bonus Registration
Statement; (v) Bonus shall request acceleration of the effective date of the Bonus registration statement immediately upon the
release of the funds in escrow so that the registration statement becomes effective no later than 48 hours from the filing of such
request unless a different time for effectiveness is agreed to in writing by Wize, in its sole discretion, and (vi) following the
Company’s consultation with its U.S. and Israeli counsels regarding the Nasdaq Listing, there is no hindrance from listing
the Ordinary Shares (or ADSs) on Nasdaq or have the SEC declare the Bonus Registration Statement (and, if applicable, Bonus Form
F-6) effective, except for the release of the Milestone Cash Consideration from the Escrow Account to the Company.

 

    18

     

    

 

12.4. Delayed
Milestone Closing. The parties hereby further agree as follows:

 

12.4.1. In
the event that the Milestone Closing shall not occur on or before the date that is twelve (12) months following the Initial Deadline
(the “Milestone End Date”), the Company may terminate the requirement to conduct the Milestone Closing by written
notice to the Investor, with a copy to the Escrow Agent (the “Company Milestone Termination Notice” and the
date of delivery of such notice, the “Company Milestone Termination Date”), in which case, (A) the liquidated
damages under Section 9 hereof shall not continue to accrue for the time following the Company Milestone Termination Date, (B)
the Milestone Cash Consideration shall be returned to the Investor in accordance with this Agreement and the Escrow Agreement,
and (C) the Milestone Shares shall be returned to the Company in accordance with this Agreement and the Escrow Agreement; provided
that, as a condition precedent to such termination right, (i) the Company shall have paid in full the liquidation damages (including
any default interest) under Section 9 hereof that accrued for the time until the Company Milestone Termination Date, (ii) the Company
shall have sent the Escrow Agent an irrevocable instruction letter confirming that the Company Milestone Termination Notice has
been sent, and (iii) the Company shall not have breached in any material respect any of its other obligations under this Agreement
in any manner that shall have caused the failure to consummate the Milestone Closing on or before the Milestone End Date.

 

12.4.2. 
In the event that the Milestone Closing shall not occur on or before the Milestone End Date, the Investor may terminate the requirement
to conduct the Milestone Closing by written notice to the Company, with a copy to the Escrow Agent (the “Investor Milestone
Termination Notice” and the date of delivery of such notice, the “Investor Milestone Termination Date”),
in which case, (A) the liquidated damages under Section 9 hereof shall not continue to accrue for the time following the Investor
Milestone Termination Date (except that the default interest on liquidated damages that have accrued through such time and not
been paid shall continue to accrue in accordance with Section 9), (B) the Milestone Cash Consideration shall be returned to the
Investor in accordance with this Agreement and the Escrow Agreement, and (C) the Milestone Shares shall be returned to the Company
in accordance with this Agreement and the Escrow Agreement; provided that, as a condition precedent to such termination
right, the Investor shall have sent the Escrow Agent an irrevocable instruction letter confirming that the Investor Milestone Termination
Notice has been sent.

 

12.4.3. For
the sake of clarity, at any time following the Closing, the Investor may waive any of the Milestone Closing Conditions (including
the Nasdaq Approval) and upon written notice thereof to the Company, with a copy to the Escrow Agent, the Company shall be required
to effect the Milestone Closing (including release from the Escrow Account of the Milestone Shares to Investor and release of the
Milestone Cash Consideration from the Escrow Account to the Company) and complying with all other applicable Milestone Closing
deliverables hereunder) within two (2) Business Days following such notice.

 

12.4.4. It
is hereby agreed that, subject to the Company’s compliance with the foregoing, the maximum liquidated damages payable to
Investor under Section 9 shall be nine and one half percent (9.5%) of the Agreed Amount (plus the applicable default interest stated
herein).

 

13. Miscellaneous

 

13.1. Amendment.
No change and/or amendment to this Agreement or any of the provisions thereof shall be valid and/or binding unless made in writing
and was signed by the Company and the Investor.

 

    19

     

    

 

13.2. Entire
Agreement. This Agreement together with the Transaction Documents contains and exhausts the full and entire understanding,
agreement and relations between the parties hereto with regard to the subject matters hereof, and shall supersede, in their entirety,
any prior document, negotiations, declaration, representation, undertaking or consent with regard to the subject matters contained
herein, whether made in writing and/or verbally, expressly and/or implicitly and/or in any other way, prior to execution of this
Agreement, including the non-binding Term Sheet entered into between the parties on October 10, 2019 (as amended from time to time).

 

13.3. English
version governs; Construction. This Agreement may be translated into another language, as a comfort translation.  However,
between this version and any other translated version of this Agreement, the English version shall prevail. The headings herein
are for convenience only, do not constitute a part of this Agreement and shall not be deemed to limit or affect any of the provisions
hereof. The language used in this Agreement will be deemed to be the language chosen by the parties to express their mutual intent,
and no rules of strict construction will be applied against any party. This Agreement shall be construed as if drafted jointly
by the parties, and no presumption or burden of proof shall arise favoring or disfavoring any party by virtue of the authorship
of any provisions of this Agreement. When used in this Agreement, (i) references to “$” or “Dollars” are
references to U.S. dollars; (ii) the words “hereof,” “herein” and “herewith” and words of similar
import will, unless otherwise stated, be construed to refer to this Agreement as a whole and not to any particular provision of
this Agreement; (iii) the words “include,” “includes” and “including” will be deemed in each
case to be followed by the words “without limitation”;.”

 

13.4. Governing
Law; Jurisdiction. The laws of the State of Israel shall apply and govern this Agreement. Exclusive jurisdiction in all matters
pertaining to and in connection with this agreement shall be vested in the competent courts of Tel Aviv, Israel.

 

13.5. Assignment.
Other than as set forth in this Agreement, no party to this Agreement may assign, transfer or encumber, in any way or form, its
rights or obligations pursuant to this Agreement, in whole or in part, without the prior written consent of the other parties to
this Agreement; provided, however, that (i) nothing in the foregoing shall be deemed to prevent the Investor to sell or
assign any of its Bonus Shares (including Milestone Shares) following the Closing (subject to lock-up provisions under applicable
securities laws) and (ii) following the Closing, the Investor may assign certain of its rights as set forth in Exhibit F
hereto.

 

13.6. Notice.
All notices, requests and other communications required or permitted under, or otherwise made in connection with, this Agreement,
shall be in writing to the address set forth below and shall be deemed to have been duly given upon the earlier of actual receipt,
or (i) personal delivery to the party to be notified, (ii) when sent, if sent by electronic mail (or, if indicated below, facsimile)
during normal business hours of the recipient, and if not sent during normal business hours, then on the recipient’s next
Business Day, (iii) five (5) days after having been sent by registered mail, return receipt requested, postage prepaid, or (iv)
one (1) Business Day after deposit with a nationally recognized overnight courier, freight prepaid, specifying next business day
delivery, with written verification of receipt, in each case, addressed to the parties’ addresses as set forth herein. Each party
may change its address for the purposes of this Agreement, by providing a written notice that shall be sent or delivered to the
other party at its address.

 

If to the Company:

 

Bonus BioGroup Ltd.

Matam Advanced Technology Park,
Building 8B, 6th floor,

P.O.B. 15143, Haifa 3190501, Israel

E-mail: office@bonus-bio.com

Attention: Dr. Shai Meretzki and Yossi Rauch

 

    20

     

    

 

with
required copies (which shall not constitute notice) to: 

 

Dr. Shai Meretzki

E-mail: shaime@bonus-bio.com

 

and

 

Yossi Rauch

E-mail: yossira@bonus-bio.com

 

and

 

Efrati Galili Confino
& Co.

Address: 28 Haarbaa
St. | Haarbaa South Tower | 19th floor

Tel Aviv 6473925

Attention: Gil Lavron,
Adv.

Email: gil@egl.co.il

 

If to Investor:

 

Wize Pharma, Inc.

24 Hanagar Street

Hod Hasharon, Israel 4527708

E-mail: noam@wizepharma.com;
or@wizepharma.com

Attention: CEO and CFO

 

with required copies
(which shall not constitute notice) to: 

 

Goldfarb
Seligman & Co.

Ampa Tower, 98 Yigal Alon Street

Tel Aviv 67891, Israel

E-mail: ido.zemach@goldfarb.com

Attention: Ido Zemach, Adv.

 

13.7. Binding
Effect; Benefit; Assignment. The provisions of this Agreement and any other Transaction Document, as the case may be, is intended
for the benefit of the parties hereto and their respective successors and permitted assigns, shall be binding upon and shall inure
to the benefit of the parties hereto and thereto and their respective permitted successors and assigns and is not for the benefit
of, nor may any provision hereof be enforced by, any other Person.

 

13.8. Counterparts.
This Agreement may be signed in any number of counterparts, each of which shall be an original, with the same effect as if the
signatures thereto and hereto were upon the same instrument. This Agreement shall become effective when each party hereto shall
have received a counterpart hereof signed by all of the other parties hereto. The exchange of a fully executed Agreement (in counterparts
or otherwise) by electronic transmission in PDF format or by facsimile shall be sufficient to bind the parties hereto to the terms
and conditions of this Agreement.

 

    21

     

    

 

13.9. Remedies.
All rights and remedies of any party hereto under this Agreement are cumulative and the exercise of one or more of such rights
or remedies shall not prejudice or impair the concurrent or subsequent exercise of other such rights or remedies given hereunder
or now or hereafter existing at law or in equity or otherwise.

 

13.10. Severability.
If any term, provision, covenant or restriction of this Agreement is held by a court of competent jurisdiction or other authority
to be invalid, void, unenforceable or against its regulatory policy, the remainder of the terms, provisions, covenants and restrictions
of this Agreement shall remain in full force and effect and shall in no way be affected, impaired or invalidated.

 

13.11. Specific
Performance. Notwithstanding anything to the contrary herein, the parties hereto agree that irreparable damage may occur if
any provision of this Agreement were not performed in accordance with the terms hereof and that the parties hereto shall be entitled
to an injunction or injunctions to prevent breaches of this Agreement or to enforce specifically the performance of the terms and
provisions of this Agreement in addition to any other remedy to which they are entitled at law or in equity.

 

13.12. Survival
of Warranties; Limitation of Liability. All representations and warranties made by the Company and the Investor shall survive
the Closing and remain in full force and effect for a period of 24 months following the Closing; provided, however, that the representations
and warranties contained in Sections 5.1.1, 5.2 and 5.3 shall survive the Closing and shall expire thirty (30) days after
the expiration date of the applicable statute of limitations. In no event shall either party be liable to the other for consequential,
special, punitive or indirect damages.

 

13.13. Publicity.
Each of the parties hereto shall coordinate with each other all publicity relating to the transactions contemplated by this Agreement,
and shall not issue any press release, immediate report or other filing with the ISA or the U.S. SEC relating to this Agreement
or the transactions contemplated by this Agreement without first obtaining the prior consent of the other or its representative,
except that neither party shall be precluded from timely making such filings or giving such notices as may be required by applicable
law or the rules of any stock exchange. Each of the parties hereto shall cooperate and shall use their reasonable efforts to agree
on the form and substance of the report to be filed by the Company with the ISA and Investor with the U.S. SEC relating to the
transactions contemplated by this Agreement.

 

13.14. TASE
Listing. For so long as the Bonus Shares, including Milestone Shares, are outstanding, the Company shall use its reasonable
commercial efforts to maintain its listing on the TASE and shall comply with all reporting requirements under applicable law in
all material respects.

 

13.15. Delays
or Omissions. Except as otherwise specifically provided for hereunder, no party shall be deemed to have waived any of his or
her or its rights hereunder or under any other agreement, instrument or document signed by any of them with respect to the subject
matter hereof unless such waiver is in writing and signed by the party waiving said right. Except as otherwise specifically provided
for hereunder, no delay or omission by any party in exercising any right with respect to the subject matter hereof shall operate
as a waiver of such right or of any such other right. A waiver on any one occasion with respect to the subject matter hereof shall
not be construed as a bar to, or waiver of, any right or remedy on any future occasion. All rights and remedies with respect to
the subject matter hereof, whether evidenced hereby or by any other agreement, instrument or document, will be cumulative, and
may be exercised separately or concurrently.

 

[Signature pages follow]

 

    22

     

    

 

IN WITNESS WHEREOF,
the parties hereto have caused this Share Purchase Agreement to be executed by their respective officers, hereunto duly authorized,
as of the day and year first above written.

 

	/s/ Yossi Ruach	 	/s/ Shai Meretzki	 
	 	 	 	 
	Bonus BioGroup Ltd.	 	 	 
	 	 	 	 
	By: Yossi Rauch	 	By: Shai Meretzki	 
	Title: Executive Chairman	 	Title: CEO and Director	 
	 	 	 	 
	/s/ Noam Danenberg	 	/s/ Or Eisenberg	 
	 	 	 	 
	Wize Pharma Inc.	 	 	 
	 	 	 	 
	By: Noam Danenberg	 	By: Or Eisenberg	 
	Title: CEO	 	Title: CFO & COOExhibit 10.3

 

FORM OF REGISTRATION RIGHTS AGREEMENT

 

THIS REGISTRATION
RIGHTS AGREEMENT (this “Agreement”), dated as of January _____, 2020, by and among Bonus BioGroup Ltd., a
company incorporated under the laws of the state of Israel (the “Company”) and Wize Pharma, Inc., a Delaware corporation
(“Wize”).

 

WHEREAS:

 

A. In connection
with (i) the Share Purchase Agreement by and among the parties hereto, dated as of January 9, 2020 (the “Share Purchase
Agreement”), and (ii) the Exchange Agreement by and among the parties hereto, dated as of January 9, 2020 (the “Exchange
Agreement” and together with the Share Purchase Agreement, the “Transaction Agreements”), the Company
has agreed, upon the terms and subject to the conditions of the Transaction Agreements, to issue and sell to the Investor ordinary
shares of the Company, no par value each (the “Ordinary Shares”).

 

B. In accordance
with the terms of the Transaction Agreements, the Company has agreed to provide certain registration rights under the Securities
Act of 1933, as amended, and the rules and regulations thereunder, or any similar successor statute (collectively, the “1933
Act”), and applicable state securities laws.

 

NOW, THEREFORE,
in consideration of the premises and the mutual covenants contained herein and other good and valuable consideration, the receipt
and sufficiency of which are hereby acknowledged, the Company and each of the Investors hereby agree as follows:

 

1. Definitions.

 

Capitalized terms used
herein and not otherwise defined herein shall have the respective meanings set forth in the Share Purchase Agreement. As used in
this Agreement, the following terms shall have the following meanings:

 

(a) “Additional
Effective Date” means the date the Additional Registration Statement is declared effective by the SEC.

 

(b) “Additional
Effectiveness Deadline” means the date which is the earlier of (i) in the event that the Additional Registration Statement
(x) is not subject to a review by the SEC, the date which is sixty (60) calendar days after the earlier of the Additional Filing
Date and the Additional Filing Deadline or (y) is subject to a review by the SEC, the date which is one hundred and thirty five
(135) calendar days after the earlier of the Additional Filing Date and the Additional Filing Deadline and (ii) the seventh (7th)
Business Day after the date the Company is notified (orally or in writing, whichever is earlier) by the SEC that such Additional
Registration Statement will not be reviewed or will not be subject to further review; provided, however, that if
the Additional Effectiveness Deadline falls on a Saturday, Sunday or other day that the SEC is closed for business, the Additional
Effectiveness Deadline shall be extended to the next Business Day on which the SEC is open for business.

 

     

     

    

 

(c) “Additional
Filing Date” means the date on which the Additional Registration Statement is filed with the SEC.

 

(d) “Additional
Filing Deadline” means if Cutback Shares are required to be included in any Additional Registration Statement, the later
of (i) the date sixty (60) days after the date substantially all of the Registrable Securities registered under the immediately
preceding Registration Statement are sold and (ii) the date six (6) months from the Initial Effective Date or the most recent Additional
Effective Date, as applicable.

 

(e) “Additional
Registrable Securities” means, (i) any Cutback Shares not previously included on a Registration Statement and (ii) any
capital stock of the Company issued or issuable with respect to the Ordinary Shares (including ADSs, if any), or the Cutback Shares,
as applicable, as a result of any stock split, stock dividend, recapitalization, exchange or similar event or otherwise, provided,
however, that such securities shall cease to qualify as Additional Registrable Securities upon the earlier to occur of: (i) the
sale thereof pursuant to and in accordance with an effective Registration Statement (other than a sale or transfer by the Initial
Holder to the Permitted Holder(s)); or (ii) such securities may be freely sold by the Holder holding thereof in the market pursuant
to Rule 144 without any limitation thereunder on volume or manner of sale.

 

(f) “Additional
Registration Statement” means a registration statement or registration statements of the Company filed under the 1933
Act covering the resale any Additional Registrable Securities.

 

(g) “Additional
Required Registration Amount” means any Cutback Shares not previously included on a Registration Statement, all subject
to adjustment as provided in Section 2(f).

 

(h) “ADSs”
shall have the meaning set forth in the Share Purchase Agreement.

 

(i) “Business
Day” means any day other than Saturday, Sunday or any other day on which commercial banks in the City of New York are
authorized or required by law to remain closed.

 

(j) “Cutback
Shares” means any of the Registrable Securities not included in all Registration Statements previously declared effective
hereunder as a result of a limitation on the maximum number of Ordinary Shares (or ADSs, if any) permitted to be registered by
the staff of the SEC pursuant to Rule 415. The number of Cutback Shares shall be allocated pro rata among the Holders.

 

(k) “effective”
and “effectiveness” refer to a Registration Statement that has been declared effective by the SEC and is available
for the resale of the Registrable Securities required to be covered thereby.

 

(l) “Effective
Date” means the Initial Effective Date and the Additional Effective Date, as applicable.

 

    2

     

    

 

(m) “Effectiveness
Deadline” means the Initial Effectiveness Deadline and the Additional Effectiveness Deadline, as applicable.

 

(n) “Eligible
Market” means the Principal Market, The New York Stock Exchange, Inc., the NYSE American, the Nasdaq Global Select Market,
or the Nasdaq Global Market.

 

(o) “Filing
Deadline” means the Initial Filing Deadline and the Additional Filing Deadline, as applicable.

 

(p) “Holder”
means (i) the Investor and its Affiliates (the “Initial Holder”) and (ii) any other holder of Ordinary Shares
(or ADSs, if applicable) which is a Permitted Holder.

 

(q) “Initial
Effective Date” means the date that the Initial Registration Statement has been declared effective by the SEC.

 

(r) “Initial
Effectiveness Deadline” means the date which is the earlier of (i) in the event that the Initial Registration Statement
(x) is not subject to a review by the SEC, forty five (45) calendar days after the Nasdaq Listing (as defined in the Share Purchase
Agreement) or (y) is subject to a full review by the SEC, one hundred and twenty (120) calendar days after the Nasdaq Listing and
(ii) the seventh (7th) Business Day after the date the Company is notified (orally or in writing, whichever is earlier)
by the SEC that such Initial Registration Statement will not be reviewed or will not be subject to further review; provided,
however, that if the Initial Effectiveness Deadline falls on a Saturday, Sunday or other day that the SEC is closed for
business, the Initial Effectiveness Deadline shall be extended to the next Business Day on which the SEC is open for business.

 

(s) “Initial
Filing Date” means the date on which the Initial Registration Statement is filed with the SEC.

 

(t) “Initial
Filing Deadline” means the date which is thirty (30) calendar days following the Nasdaq Listing.

 

(u) “Initial
Registrable Securities” means (i) the Bonus Shares (as defined in the Share Purchase Agreement), and for the avoidance
of doubt only, including the Initial Shares, any Ordinary Shares issued in connection with adjustments, and any ADSs into which
such shares have been converted (or can be converted), and (ii) any capital stock of the Company issued or issuable, with respect
to the securities described in clause (i) as a result of any stock split, stock dividend, recapitalization, exchange or similar
event or otherwise, provided, however, that such securities shall cease to qualify as Initial Registrable Securities upon the earlier
to occur of: (i) the sale thereof pursuant to and in accordance with an effective Registration Statement (other than a sale or
transfer by the Initial Holder to the Permitted Holder(s)); or (ii) such securities may be freely sold by the Investor holding
thereof in the market pursuant to Rule 144 without any limitation thereunder on volume or manner of sale.

 

    3

     

    

 

(v) “Initial
Registration Statement” means a registration statement or registration statements of the Company filed under the 1933
Act covering the resale of Initial Registrable Securities.

 

(w) “Initial
Required Registration Amount” means the sum of (i) the number of Ordinary Shares issued under the Transaction Agreements
(including the Milestone Shares) plus (ii) the maximum number of additional Ordinary Shares issuable pursuant to the Transaction
Agreements (such as pursuant to Section 9 of the Share Purchase Agreement), in each case as of the Trading Day immediately preceding
the applicable date of determination, subject to adjustment as provided in Section 2(f).

 

(x) “Investor”
means Wize and any transferee or assignee thereof to whom Wize assigns its rights under this Agreement and who agrees to become
bound by the provisions of this Agreement in accordance with Section ‎10 (such assignee
or transferee, the “Permitted Holder”) and any transferee or assignee thereof to whom a transferee or assignee
assigns its rights under this Agreement and who agrees to become bound by the provisions of this Agreement in accordance with Section
‎10.

 

(y) “Person”
means an individual, a limited liability company, a partnership, a joint venture, a corporation, a trust, an unincorporated organization
and a government or any department or agency thereof.

 

(z) “Principal
Market” means the Nasdaq Capital Market.

 

(aa) “register,”
“registered,” and “registration” refer to a registration effected by preparing and filing one
or more Registration Statements (as defined below) in compliance with the 1933 Act and pursuant to Rule 415, and the declaration
or ordering of effectiveness of such Registration Statement(s) by the SEC.

 

(bb) “Registrable
Securities” means the Initial Registrable Securities and the Additional Registrable Securities.

 

(cc) “Registration
Statement” means the Initial Registration Statement and the Additional Registration Statement, as applicable.

 

(dd) “Required
Holders” means the holders of at least a majority of the Registrable Securities.

 

(ee) “Required
Registration Amount” means either the Initial Required Registration Amount or the Additional Required Registration Amount,
as applicable.

 

(ff) “Rule
144” means Rule 144 promulgated under the 1933 Act or any successor rule or regulation of the SEC that may at any time
permit the Investors to sell securities of the Company to the public without registration.

 

(gg) “Rule
415” means Rule 415 promulgated under the 1933 Act or any successor rule providing for offering securities on a continuous
or delayed basis.

 

    4

     

    

 

(hh) “SEC”
means the United States Securities and Exchange Commission.

 

(ii) “Trading
Day” means any day on which the Ordinary Shares (or, if the Nasdaq Listing entails an ADR Program, the ADSs) are traded
on the Principal Market, or, if the Principal Market is not the principal trading market for the Ordinary Shares (or ADSs if applicable)
on such day, then on the principal securities exchange or securities market on which the Ordinary Shares (or ADSs if applicable)
are then traded, other than the Tel Aviv Stock Exchange.

 

2. Demand
Registration.

 

(a) Initial
Mandatory Registration. The Company shall prepare, and, as soon as practicable but in no event later than the Initial Filing
Deadline, file with the SEC the Initial Registration Statement on Form S-3 or Form F-3, as applicable, or if Form S-3 and Form
F-3 are unavailable, Form S-1 or Form F-1, as applicable, covering the resale of all of the Initial Registrable Securities. The
Initial Registration Statement prepared pursuant hereto shall register for resale at least the number of Ordinary Shares equal
to the Initial Required Registration Amount determined as of the date the Initial Registration Statement is initially filed with
the SEC, subject to adjustment as provided in Section 2(f). The Initial Registration Statement shall contain (except if otherwise
directed by the Required Holders) the “Plan of Distribution” and “Selling Shareholders” sections
in substantially the form attached hereto as Exhibit A. The Company shall use its reasonable commercial efforts to have
the Initial Registration Statement declared effective by the SEC as soon as practicable, but in no event later than the Initial
Effectiveness Deadline. No later than the second (2nd) Business Day following the Initial Effective Date, the Company
shall file with the SEC in accordance with Rule 424 under the 1933 Act the final prospectus to be used in connection with sales
pursuant to such Initial Registration Statement.

 

(b) Additional
Mandatory Registrations. The Company shall prepare, and, as soon as practicable but in no event later than the Additional Filing
Deadline, file with the SEC an Additional Registration Statement on Form S-3 or Form F-3, as applicable, or if Form S-3 and Form
F-3 are unavailable, Form S-1 or Form F-1, as applicable, covering the resale of all of the Additional Registrable Securities not
previously registered on an Additional Registration Statement hereunder. To the extent the staff of the SEC does not permit the
Additional Required Registration Amount to be registered on an Additional Registration Statement, the Company shall file Additional
Registration Statements successively attempting to register on each such Additional Registration Statement the maximum number of
remaining Additional Registrable Securities until the Additional Required Registration Amount has been registered with the SEC.
Each Additional Registration Statement prepared pursuant hereto shall register for resale at least that number of Ordinary Shares
equal to the Additional Required Registration Amount determined as of the date such Additional Registration Statement is initially
filed with the SEC, subject to adjustment as provided in Section 2(f). Each Additional Registration Statement shall contain (except
if otherwise directed by the Required Holders) the “Plan of Distribution” and “Selling Shareholders”
sections in substantially the form attached hereto as Exhibit A. The Company shall use its reasonable commercial efforts
to have each Additional Registration Statement declared effective by the SEC as soon as practicable, but in no event later than
the Additional Effectiveness Deadline. No later than the second (2nd) Business Day following the Additional Effective
Date, the Company shall file with the SEC in accordance with Rule 424 under the 1933 Act the final prospectus to be used in connection
with sales pursuant to such Additional Registration Statement.

 

    5

     

    

 

(c) Allocation
of Registrable Securities. The initial number of Registrable Securities included in any Registration Statement and any increase
or decrease in the number of Registrable Securities included therein shall be allocated pro rata among the Investors based on the
number of Registrable Securities held by each Investor at the time the Registration Statement covering such initial number of Registrable
Securities or increase or decrease thereof is declared effective by the SEC. In the event that an Investor sells or otherwise transfers
any of such Investor’s Registrable Securities, each transferee shall be allocated a pro rata portion of the then remaining number
of Registrable Securities included in such Registration Statement for such transferor. Any Ordinary Shares included in a Registration
Statement and which remain allocated to any Person which ceases to hold any Registrable Securities covered by such Registration
Statement shall be allocated to the remaining Investors, pro rata based on the number of Registrable Securities then held by such
Investors which are covered by such Registration Statement. In no event shall the Company include any securities other than Registrable
Securities on any Registration Statement without the prior written consent of the Required Holders.

 

(d) Legal Counsel.
Subject to Section ‎6 hereof, Wize shall have the right to select one legal counsel to
review and monitor any registration pursuant to this Section 2 (“Legal Counsel”), which shall be such counsel
as designated by Wize, and reasonably acceptable to the Company, provided such counsel shall be familiar with United States Federal
securities laws. The Company shall be responsible for the fees and expenses of Legal Counsel, up to an aggregate cumulative amount
of $10,000. The consent of the Legal Counsel shall not be required for the Company to take any action in connection with this Agreement;
provided that it shall consider such Legal Counsel’s timely comments in good faith..

 

(e) Ineligibility
for Form S-3 and Form F-3. In the event that Form S-3 and Form F-3, as applicable, are not available for the registration of
the resale of Registrable Securities hereunder, the Company shall (i) register the resale of the Registrable Securities on Form
S-1 or Form F-1 (as applicable) or another appropriate form reasonably acceptable to the Required Holders and (ii) undertake to
register the Registrable Securities on Form S-3 or Form F-3 (as applicable) as soon as such form is available, provided that the
Company shall maintain the effectiveness of the Registration Statement then in effect until such time as a Registration Statement
on Form S-3 or Form F-3 (as applicable) covering the Registrable Securities has been declared effective by the SEC.

 

(f) Sufficient
Number of Shares Registered. In the event the number of shares available under a Registration Statement filed pursuant to Section
2(a) or Section 2(b) is insufficient to cover the Required Registration Amount of Registrable Securities required to be covered
by such Registration Statement or an Investor’s allocated portion of the Registrable Securities pursuant to Section 2(c), the Company
shall amend the applicable Registration Statement, or file a new Registration Statement (on the short form available therefor,
if applicable), or both, so as to cover at least the Required Registration Amount as of the Trading Day immediately preceding the
date of the filing of such amendment or new Registration Statement, in each case, as soon as practicable, but in any event not
later than thirty (30) days after the necessity therefor arises. The Company shall use its reasonable commercial efforts to cause
such amendment and/or new Registration Statement to become effective as soon as practicable following the filing thereof. For purposes
of the foregoing provision, the number of shares available under a Registration Statement shall be deemed “insufficient to
cover all of the Registrable Securities” if at any time the number of Ordinary Shares available for resale under the Registration
Statement is less than the Required Registration Amount as of such time.

 

    6

     

    

 

(g) Effect
of Failure to File and Obtain and Maintain Effectiveness of Registration Statement. If (i) the Initial Registration Statement
when declared effective fails to register the Initial Required Registration Amount of Initial Registrable Securities (a “Registration
Failure”), (ii) a Registration Statement covering all of the Registrable Securities required to be covered thereby and
required to be filed by the Company pursuant to this Agreement is (A) not filed with the SEC on or before the applicable Filing
Deadline (a “Filing Failure”) or (B) not declared effective by the SEC on or before the applicable Effectiveness
Deadline, (an “Effectiveness Failure”) or (iii) on any day after the applicable Effective Date sales of all of
the Registrable Securities required to be included on such Registration Statement cannot be made (other than during a Non-Penalty
Grace Period, as such term is defined below) pursuant to such Registration Statement or otherwise (including, without limitation,
because of the suspension of trading or any other limitation imposed by an Eligible Market or a failure to keep such Registration
Statement effective) (a “Maintenance Failure”) then, as partial relief for the damages to any holder by reason
of any such delay in or reduction of its ability to sell the Ordinary Shares (which remedy shall not be exclusive of any other
remedies available at law or in equity, including, without limitation, specific performance or the additional obligation of the
Company to register any Cutback Shares), the Company shall pay to each holder of Registrable Securities relating to such Registration
Statement an amount equal to (A) a fraction of such holder’s Registrable Securities that are required to be included in an
effective Registration Statement under this Agreement divided by the aggregate number of Registrable Securities required
to be included in an effective Registration Statement under this Agreement by all holders multiplied by (B) one percent
(1%) of the Agreed Amount (as such term is defined in the Share Purchase Agreement) on each of the following dates: (i) the day
of a Registration Failure, (ii) the day of a Filing Failure; (iii) the day of an Effectiveness Failure; (iv) the initial day of
a Maintenance Failure; (v) on the thirtieth day after the date of a Registration Failure and every thirtieth day thereafter (pro
rated for periods totaling less than thirty days) until such Registration Failure is cured, (vi) on the thirtieth day after the
date of a Filing Failure and every thirtieth day thereafter (pro rated for periods totaling less than thirty days) until such Filing
Failure is cured; (vii) on the thirtieth day after the date of an Effectiveness Failure and every thirtieth day thereafter (pro-rated
for periods totaling less than thirty days) until such Effectiveness Failure is cured; and (viii) on the thirtieth day after the
initial date of a Maintenance Failure and every thirtieth day thereafter (pro rated for periods totaling less than thirty days)
until such Maintenance Failure is cured; it being clarified that, in each such case, such Registration Delay Payments shall not
continue to accrue with respect to such Holder’s securities that are no longer Registrable Securities. The payments to which
a holder shall be entitled pursuant to this Section 2(g) are referred to herein as “Registration Delay Payments.”
Registration Delay Payments shall be paid on the earlier of (I) the dates set forth above and (II) the fifth Business Day after
the event or failure giving rise to the Registration Delay Payments is cured. In the event the Company fails to make Registration
Delay Payments in a timely manner, such Registration Delay Payments shall bear interest beginning on the tenth (10th)
day following the due date thereof, calculated at the annual rate of two percent (2.0%) over the prime interest rate quoted by
the Wall Street Journal on the date such payment is due, compounded monthly; provided, however, that in no event shall such
annual interest rate exceed the maximum rate allowed under applicable law. Each payment of Registration Delay Payments may be made,
at the Company’s discretion, in either cash or Ordinary Shares. In case the payment is in Ordinary Shares, (A) the number of which
shall be determined by dividing (x) the applicable Registration Delay Payment by (y) the VWAP on Nasdaq during a 30 trading days
prior to the date giving rise to such Registration Delay Payment, and (B) such Ordinary Shares shall be validly issued, fully paid
and nonassessable and free from all preemptive or similar rights, taxes, liens, charges and other encumbrances, and (C) for the
sake of clarity, such shares shall be considered Registrable Securities for all intents and purposes hereof (unless they may be
freely sold by the Holder in the market pursuant to Rule 144 without any limitation thereunder on volume or manner of sale).

 

    7

     

    

 

(h) Notwithstanding
anything to the contrary hereunder, at any time after the Effective Date, the Company may delay the disclosure of material, non-public
information concerning the Company the disclosure of which at the time is not, in the good faith opinion of the Board of Directors
of the Company after consultation with its counsel, in the best interest of the Company and, in the opinion of counsel to the Company,
otherwise required in order to maintain effectiveness of a Registration Statement (a “Grace Period”); provided,
that the Company shall promptly (i) notify the Investors in writing of the existence of material, non-public information giving
rise to a Grace Period (provided that in each notice the Company will not disclose the content of such material, non-public information
to the Investors) and the date on which the Grace Period will begin, and (ii) notify the Investors in writing of the date on which
the Grace Period ends; and, provided further, that (A) no Grace Period shall exceed twenty (20) consecutive days and during
any three hundred sixty five (365) day period such Grace Periods shall not exceed an aggregate of forty five (45) days and the
first day of any Grace Period must be at least ten (10) Trading Days after the last day of any prior Grace Period, and (B) if the
Grace Period shall exceed (i) five (5) consecutive days, or (ii) during any three hundred sixty five (365) day period, an aggregate
of twenty (20) days, (each, a “Non-Penalty Grace Period”), then such excess days (each, a “Penalty Grace
Period”) shall be counted towards the days of the Maintenance Failure under Section 3(g). For purposes of determining
the length of a Grace Period above, the Grace Period shall begin on and include the date the Investors receive the notice referred
to in clause (i) and shall end on and include the later of the date the Investors receive the notice referred to in clause (ii)
and the date referred to in such notice.

 

3. Related
Obligations.

 

At such time as the Company
is obligated to file a Registration Statement with the SEC pursuant to Section 2(a), 2(b) or 2(e), the Company will use its reasonable
commercial efforts to effect the registration of the Registrable Securities in accordance with the intended method of disposition
thereof and, pursuant thereto, the Company shall have the following obligations:

 

(a) The Company
shall prepare and file with the SEC a Registration Statement with respect to the Registrable Securities and use its reasonable
commercial efforts to cause such Registration Statement relating to the Registrable Securities to become effective as soon as practicable
after such filing (but in no event later than the Effectiveness Deadline). The Company shall keep each Registration Statement effective
at all times until the earlier of: (i) the date as of which the Holders shall have sold all of the Registrable Securities covered
by such Registration Statement (other than a sale or transfer by the Initial Holder to the Permitted Holder(s)); and (ii) the date
as of which all the Registrable Securities may be freely sold by the Holders holding thereof in the market pursuant to Rule 144
without limitation thereunder on volume or manner of sale (the “Registration Period”). The Company shall ensure
that each Registration Statement (including any amendments or supplements thereto and prospectuses contained therein) shall not
contain any untrue statement of a material fact or omit to state a material fact required to be stated therein, or necessary to
make the statements therein (in the case of prospectuses, in the light of the circumstances in which they were made) not misleading.
The term “reasonable commercial efforts” shall mean, among other things, that the Company shall submit to the SEC, within
two (2) Business Days after the Company learns that no review of a particular Registration Statement will be made by the staff
of the SEC or that the staff has no further comments on a particular Registration Statement, as the case may be, a request for
acceleration of effectiveness of such Registration Statement to a time and date not later than two (2) Business Days after the
submission of such request. The Company shall respond in writing to comments made by the SEC in respect of a Registration Statement
as soon as practicable.

 

    8

     

    

 

(b) The Company
shall prepare and file with the SEC such amendments (including post-effective amendments) and supplements to a Registration Statement
and the prospectus used in connection with such Registration Statement, which prospectus is to be filed pursuant to Rule 424 promulgated
under the 1933 Act, as may be necessary to keep such Registration Statement effective at all times during the Registration Period,
and, during such period, comply with the provisions of the 1933 Act with respect to the disposition of all Registrable Securities
of the Company covered by such Registration Statement until the early to occur of: (i) such time as all of such Registrable Securities
shall have been disposed of in accordance with the intended methods of disposition by the seller or sellers thereof as set forth
in such Registration Statement (other than a sale or transfer by the Initial Holder to the Permitted Holder(s)); and (ii) such
time all Registrable Securities may be freely sold by the Holders holding thereof in the market pursuant to Rule 144 without any
limitation thereunder on volume or manner of sale. In the case of amendments and supplements to a Registration Statement which
are required to be filed pursuant to this Agreement (including pursuant to this Section 3(b)) by reason of the Company filing a
report on Form 10-K, Form 10-Q or Form 8-K or any analogous report under the Securities Exchange Act of 1934, as amended (the “1934
Act”), the Company shall have incorporated such report by reference into such Registration Statement, if applicable, or
shall file such amendments or supplements with the SEC on the same day on which the 1934 Act report is filed which created the
requirement for the Company to amend or supplement such Registration Statement.

 

(c) The Company
shall permit Legal Counsel to review and comment upon (i) a Registration Statement at least three (3) Business Days prior to its
filing with the SEC and (ii) all amendments and supplements to all Registration Statements (except for Annual Reports on Form 10-K/20-F,
Quarterly Reports on Form 10-Q/6-K, Current Reports on Form 8-K/6-K, and any similar or successor reports or analogous reports
under the 1934 Act) within a reasonable number of days prior to their filing with the SEC. In addition, if requested by an Investor,
the Company shall permit each such Investor to review and comment on the Selling Shareholder section of each Registration Statement
and all amendments and supplements to all Registration Statements at least two Business Days prior to its filing with the SEC.
Unless publicly filed with the SEC, the Company shall furnish to Legal Counsel, without charge, (i) copies of any correspondence
from the SEC or the staff of the SEC to the Company or its representatives relating to any Registration Statement, and (ii) promptly
after the same is prepared and filed with the SEC, one copy of any Registration Statement and any amendment(s) thereto, including
financial statements and schedules, all documents incorporated therein by reference, if requested by an Investor, and all exhibits.
In addition, the Company shall deliver to the Legal Counsel, upon the effectiveness of any Registration Statement, one copy of
the prospectus included in such Registration Statement and all amendments and supplements thereto. The Company shall reasonably
cooperate with Legal Counsel in performing the Company’s obligations pursuant to this Section ‎3.

 

    9

     

    

 

(d) The Company
shall furnish to each Investor whose Registrable Securities are included in any Registration Statement, without charge, following
request of such Investor, (i) promptly after the same is prepared and filed with the SEC, at least one copy of such Registration
Statement and any amendment(s) thereto, including financial statements and schedules, if requested by an Investor, all exhibits
and each preliminary prospectus (which may be delivered by email), (ii) upon the effectiveness of any Registration Statement, one
copy of the prospectus included in such Registration Statement and all amendments and supplements thereto (which may be delivered
by email) and (iii) such other documents, including copies of any preliminary or final prospectus, as such Investor may reasonably
request from time to time in order to facilitate the disposition of the Registrable Securities owned by such Investor.

 

(e) The Company
shall use its reasonable commercial efforts to (i) register and qualify, unless an exemption from registration and qualification
applies, the resale by Investors of the Registrable Securities covered by a Registration Statement under such other securities
or “blue sky” laws of all applicable jurisdictions in the United States (the “Jurisdictions”), (ii)
prepare and file in those Jurisdictions such amendments (including post-effective amendments) and supplements to such registrations
and qualifications as may be necessary to maintain the effectiveness thereof during the Registration Period, (iii) take such other
actions as may be necessary to maintain such registrations and qualifications in effect at all times during the Registration Period,
and (iv) take all other actions reasonably necessary or advisable to qualify the Registrable Securities for sale in such Jurisdictions;
provided, however, that the Company shall not be required in connection therewith or as a condition thereto to (x) qualify to do
business in any jurisdiction where it would not otherwise be required to qualify but for this Section 3(e), (y) subject itself
to general taxation in any such jurisdiction, or (z) file a general consent to service of process in any such jurisdiction.

 

(f) The Company
shall promptly notify Legal Counsel and each Investor who holds Registrable Securities of the receipt by the Company of any notification
with respect to the suspension of the registration or qualification of any of the Registrable Securities for sale under the securities
or “blue sky” laws of any jurisdiction in the United States or its receipt of actual notice of the initiation or threatening
of any proceeding for such purpose.

 

(g) The Company
shall notify Legal Counsel and each Investor in writing of the happening of any event, as promptly as practicable after becoming
aware of such event but in any event on the same Trading Day as such event, as a result of which the prospectus included in a Registration
Statement, as then in effect, includes an untrue statement of a material fact or omission to state a material fact required to
be stated therein or necessary to make the statements therein, in the light of the circumstances under which they were made, not
misleading (provided that in no event shall such notice contain any material, nonpublic information), and promptly prepare a supplement
or amendment to such Registration Statement to correct such untrue statement or omission, and deliver, following request of an
Investor, one copy of such supplement or amendment to Legal Counsel and each Investor (which may be delivered by email). The Company
shall also promptly notify Legal Counsel and each Investor in writing (i) when a prospectus or any prospectus supplement or post-effective
amendment has been filed, and when a Registration Statement or any post-effective amendment has become effective (notification
of such effectiveness shall be delivered to Legal Counsel and each Investor by facsimile or email on the same day of such effectiveness),
(ii) of any request by the SEC for amendments or supplements to a Registration Statement or related prospectus or related information
and (iii) of the Company’s reasonable determination that a post-effective amendment to a Registration Statement would be appropriate.
No later than the second (2nd) Business Day following the date any post-effective amendment has become effective, the
Company shall file with the SEC in accordance with Rule 424 under the 1933 Act the final prospectus to be used in connection with
sales pursuant to such Registration Statement.

 

    10

     

    

 

(h) The Company
shall use its reasonable commercial efforts to prevent the issuance of any stop order or other suspension of effectiveness of a
Registration Statement, or the suspension of the qualification of any of the Registrable Securities for sale in any jurisdiction
and, if such an order or suspension is issued, to obtain the withdrawal of such order or suspension at the earliest possible moment
and to promptly, but in no event later than the Trading Day of such issuance, notify Legal Counsel and each Investor who holds
Registrable Securities of the issuance of such order or suspension and the resolution thereof or its receipt of actual notice of
the initiation or threat of any proceeding for such purpose.

 

(i) Notwithstanding
anything to the contrary contained herein, in no event shall the Company be permitted to name any Investor or affiliate of an Investor
as an underwriter without the prior written consent of such Investor.

 

(j) The Company
shall hold in confidence and not make any disclosure of information concerning an Investor provided to the Company unless (i) disclosure
of such information is reasonably necessary, as determined in good faith by the Company, to comply with federal or state securities
laws, (ii) the disclosure of such information is necessary to avoid or correct a misstatement or omission in any Registration Statement,
(iii) the release of such information is ordered pursuant to a subpoena or other final, non-appealable order from a court or governmental
body of competent jurisdiction, or (iv) such information has been made generally available to the public other than by disclosure
in violation of this Agreement. The Company agrees that it shall, upon learning that disclosure of such information concerning
an Investor is sought in or by a court or governmental body of competent jurisdiction or through other means, give prompt written
notice (to the extent the Company is permitted to do so) to such Investor and allow such Investor, at the Investor’s expense, to
undertake appropriate action to prevent disclosure of, or to obtain a protective order for, such information.

 

(k) Reserved.

 

(l) Reserved.

 

    11

     

    

 

(m) If requested
by an Investor, the Company shall as soon as practicable (i) incorporate in a prospectus supplement or post-effective amendment
such information as an Investor reasonably requests to be included therein relating to the sale and distribution of Registrable
Securities, including, without limitation, information with respect to the number of Registrable Securities being offered or sold,
the purchase price being paid therefor and any other terms of the offering of the Registrable Securities to be sold in such offering;
(ii) make all required filings of such prospectus supplement or post-effective amendment after being notified of the matters to
be incorporated in such prospectus supplement or post-effective amendment; and (iii) supplement or make amendments to any Registration
Statement if reasonably requested by an Investor holding any Registrable Securities.

 

(n) The Company
shall use its reasonable commercial efforts to cause the Registrable Securities covered by a Registration Statement to be registered
with or approved by such other governmental agencies or authorities as may be necessary to consummate the disposition of such Registrable
Securities in the Jurisdictions.

 

(o) Reserved.

 

(p) The Company
shall otherwise use its reasonable commercial efforts to comply with all applicable rules and regulations of the SEC in connection
with any registration hereunder.

 

(q) Within two
(2) Business Days after a Registration Statement which covers Registrable Securities is declared effective by the SEC, the Company
shall deliver, and shall cause legal counsel for the Company to deliver, to the transfer agent for such Registrable Securities
(with copies to the Investors whose Registrable Securities are included in such Registration Statement) confirmation that such
Registration Statement has been declared effective by the SEC in customary form reasonably acceptable to the Required Holders.

 

(r) Reserved.

 

(s) Reserved.

 

(t) Neither the
Company nor any of its Subsidiaries has entered, as of the date hereof, nor shall the Company or any of its Subsidiaries, on or
after the date of this Agreement, enter into any agreement with respect to its securities, that would have the effect of impairing
the rights granted to the Investors in this Agreement or otherwise conflicts with the provisions hereof.

 

(u) In the event
that the Company implements an ADR Program, the Company shall, at Investors’ request at any time and from time to time, cause
part or all of the Bonus Shares owned by the Investors to be converted into ADRs, at the Company’s expense, and this Agreement
shall apply mutatis mutandis to the ADRs held by the Investors in place of the Ordinary Shares.

 

    12

     

    

 

4. Obligations
of the Investors.

 

(a) At least five
(5) Business Days prior to the first anticipated Filing Date of a Registration Statement, the Company shall notify each Investor
in writing of the information the Company requires from each such Investor if such Investor elects to have any of such Investor’s
Registrable Securities included in such Registration Statement. It shall be a condition precedent to the obligations of the Company
to complete any registration pursuant to this Agreement with respect to the Registrable Securities of a particular Investor that
such Investor shall furnish to the Company such information regarding itself, the Registrable Securities held by it and the intended
method of disposition of the Registrable Securities held by it as shall be reasonably required to effect and maintain the effectiveness
of the registration of such Registrable Securities and shall execute such documents in connection with such registration as the
Company may reasonably request.

 

(b) Each Investor,
by such Investor’s acceptance of the Registrable Securities, agrees to cooperate with the Company as reasonably requested by the
Company in connection with the preparation and filing of any Registration Statement hereunder, unless such Investor has notified
the Company in writing of such Investor’s election to exclude all of such Investor’s Registrable Securities from such Registration
Statement.

 

(c) Each Investor
agrees that, upon receipt of any notice from the Company of the happening of any event of the kind described in Section 2(h), Section
3(f) or Section 3(g), such Investor will immediately discontinue disposition of Registrable Securities pursuant to any Registration
Statement(s) covering such Registrable Securities until such Investor’s receipt of copies of the supplemented or amended prospectus
as contemplated by Section 3(f) or Section 3(g) or receipt of notice that no supplement or amendment is required.

 

(d) Each Investor
covenants and agrees that it will comply with the prospectus delivery requirements of the 1933 Act as applicable to it or an exemption
therefrom in connection with sales of Registrable Securities pursuant to the Registration Statement.

 

5. Expenses
of Registration.

 

All reasonable expenses,
other than underwriting discounts and commissions, incurred in connection with registrations, filings or qualifications pursuant
to Sections 2 and 3 hereof, including, without limitation, all registration, listing and qualifications fees, printers and accounting
fees, and fees and disbursements of counsel for the Company shall be paid by the Company.

 

    13

     

    

 

6. Indemnification.

 

In the event any Registrable
Securities are included in a Registration Statement under this Agreement:

  

(a) To the fullest
extent permitted by law, the Company will, and hereby does, indemnify, hold harmless and defend each Investor, the directors, officers,
partners, members, employees, agents, representatives of, and each Person, if any, who controls any Investor within the meaning
of the 1933 Act or the 1934 Act (each, an “Indemnified Person”), against any losses, claims, damages, liabilities,
judgments, fines, penalties, charges, costs, reasonable attorneys’ fees, amounts paid in settlement or expenses, joint or several
(collectively, “Claims”), incurred in investigating, preparing or defending any action, claim, suit, inquiry,
proceeding, investigation or appeal taken from the foregoing by or before any court or governmental, administrative or other regulatory
agency, body or the SEC, whether pending or threatened, whether or not an indemnified party is or may be a party thereto (“Indemnified
Damages”), to which any of them may become subject insofar as such Claims (or actions or proceedings, whether commenced
or threatened, in respect thereof) arise out of or are based upon: (i) any untrue statement or alleged untrue statement of a material
fact in a Registration Statement or any post-effective amendment thereto or in any filing made in connection with the qualification
of the offering under the securities or other “blue sky” laws of any jurisdiction in which Registrable Securities are
offered (“Blue Sky Filing”), or the omission or alleged omission to state a material fact required to be stated
therein or necessary to make the statements therein not misleading, (ii) any untrue statement or alleged untrue statement of a
material fact contained in any preliminary prospectus if used prior to the effective date of such Registration Statement, or contained
in the final prospectus (as amended or supplemented, if the Company files any amendment thereof or supplement thereto with the
SEC) or the omission or alleged omission to state therein any material fact necessary to make the statements made therein, in light
of the circumstances under which the statements therein were made, not misleading, or (iii) any violation or alleged violation
by the Company of the 1933 Act, the 1934 Act, any other law, including, without limitation, any state securities law, or any rule
or regulation thereunder relating to the offer or sale of the Registrable Securities pursuant to a Registration Statement (the
matters in the foregoing clauses (i) through (iii) being, collectively, “Violations”). Subject to Section 6(c),
the Company shall reimburse the Indemnified Persons, promptly as such expenses are incurred and are due and payable, for any legal
fees or other reasonable expenses incurred by them in connection with investigating or defending any such Claim. Notwithstanding
anything to the contrary contained herein, the indemnification agreement contained in this Section 6(a): (i) shall not apply to
a Claim by an Indemnified Person arising out of or based upon a Violation which occurs in reliance upon and in conformity with
information furnished in writing to the Company by such Indemnified Person for such Indemnified Person expressly for use in connection
with the preparation of the Registration Statement or any such amendment thereof or supplement thereto, if such prospectus was
timely made available by the Company pursuant to Section 3(d); (ii) shall not apply to amounts paid in settlement of any Claim
if such settlement is effected without the prior written consent of the Company, which consent shall not be unreasonably withheld
or delayed and (iii) shall not apply to Claims based solely upon any conduct by such Indemnified Person which is finally judicially
determined to constitute fraud, gross negligence, willful misconduct or malfeasance. Such indemnity shall remain in full force
and effect regardless of any investigation made by or on behalf of the Indemnified Person and shall survive the transfer of the
Registrable Securities by the Investors pursuant to Section 9.

 

    14

     

    

 

(b) In connection
with any Registration Statement in which an Investor is participating, each such Investor agrees to severally and not jointly indemnify,
hold harmless and defend, to the same extent and in the same manner as is set forth in Section 6(a), the Company, each of its directors,
each of its officers who signs the Registration Statement and each Person, if any, who controls the Company within the meaning
of the 1933 Act or the 1934 Act (each, an “Indemnified Party”), against any Claim or Indemnified Damages to which
any of them may become subject, under the 1933 Act, the 1934 Act or otherwise, insofar as such Claim or Indemnified Damages arise
out of or are based upon any Violation, in each case to the extent, and only to the extent, that such Violation occurs in reliance
upon and in conformity with written information furnished to the Company by such Investor expressly for use in connection with
such Registration Statement; and, subject to Section 6(c), such Investor shall reimburse the Indemnified Party for any legal or
other expenses reasonably incurred by an Indemnified Party in connection with investigating or defending any such Claim; provided,
however, that the indemnity agreement contained in this Section 6(b) and the agreement with respect to contribution contained in
Section 7 shall not apply to amounts paid in settlement of any Claim if such settlement is effected without the prior written consent
of such Investor, which consent shall not be unreasonably withheld or delayed; provided, further, however, that the Investor shall
be liable under this Section 6(b) for only that amount of a Claim or Indemnified Damages as does not exceed the net proceeds to
such Investor as a result of the sale of Registrable Securities pursuant to such Registration Statement. Such indemnity shall remain
in full force and effect regardless of any investigation made by or on behalf of such Indemnified Party and shall survive the transfer
of the Registrable Securities by the Investors pursuant to Section 9.

 

(c) Promptly after
receipt by an Indemnified Person or Indemnified Party under this Section ‎6 of notice
of the commencement of any action or proceeding (including any governmental action or proceeding) involving a Claim, such Indemnified
Person or Indemnified Party shall, if a Claim in respect thereof is to be made against any indemnifying party under this Section6,
deliver to the indemnifying party a written notice of the commencement thereof, and the indemnifying party shall have the right
to participate in, and, to the extent the indemnifying party so desires, jointly with any other indemnifying party similarly noticed,
to assume control of the defense thereof with counsel mutually satisfactory to the indemnifying party and the Indemnified Person
or the Indemnified Party, as the case may be; provided, however, that an Indemnified Person or Indemnified Party shall have the
right to retain its own counsel with the fees and expenses of not more than one counsel for all such Indemnified Person or Indemnified
Party to be paid by the indemnifying party, if, in the reasonable opinion of counsel retained by the Indemnified Person or Indemnified
Party, as applicable, the representation by such counsel of the Indemnified Person or Indemnified Party, as the case may be, and
the indemnifying party would be inappropriate due to actual or potential differing interests between such Indemnified Person or
Indemnified Party and any other party represented by such counsel in such proceeding. In the case of an Indemnified Person, legal
counsel referred to in the immediately preceding sentence shall be selected by the Investors holding at least a majority in interest
of the Registrable Securities included in the Registration Statement to which the Claim relates. The Indemnified Party or Indemnified
Person shall reasonably cooperate with the indemnifying party in connection with any negotiation or defense of any such action
or Claim by the indemnifying party and shall furnish to the indemnifying party all information reasonably available to the Indemnified
Party or Indemnified Person which relates to such action or Claim. The indemnifying party shall keep the Indemnified Party or Indemnified
Person fully apprised at all times as to the status of the defense or any settlement negotiations with respect thereto. No indemnifying
party shall be liable for any settlement of any action, claim or proceeding effected without its prior written consent, provided,
however, that the indemnifying party shall not unreasonably withhold, delay or condition its consent. No indemnifying party shall,
without the prior written consent of the Indemnified Party or Indemnified Person, consent to entry of any judgment or enter into
any settlement or other compromise which does not include as an unconditional term thereof the giving by the claimant or plaintiff
to such Indemnified Party or Indemnified Person of a release from all liability in respect to such Claim or litigation and such
settlement shall not include any admission as to fault on the part of the Indemnified Party. Following indemnification as provided
for hereunder, the indemnifying party shall be subrogated to all rights of the Indemnified Party or Indemnified Person with respect
to all third parties, firms or corporations relating to the matter for which indemnification has been made. The failure to deliver
written notice to the indemnifying party within a reasonable time of the commencement of any such action shall not relieve such
indemnifying party of any liability to the Indemnified Person or Indemnified Party under this Section 6, except to the extent that
the indemnifying party is prejudiced in its ability to defend such action.

 

    15

     

    

 

(d) The indemnification
required by this Section 6 shall be made by periodic payments of the amount thereof during the course of the investigation or defense,
as and when bills are received or Indemnified Damages are incurred.

 

(e) The indemnity
agreements contained herein shall be in addition to (i) any cause of action or similar right of the Indemnified Party or Indemnified
Person against the indemnifying party or others, and (ii) any liabilities the indemnifying party may be subject to pursuant to
the law.

 

7. Contribution.

 

To the extent any indemnification
by an indemnifying party is prohibited or limited by law, the indemnifying party agrees to make the maximum contribution with respect
to any amounts for which it would otherwise be liable under Section 6 to the fullest extent permitted by law; provided, however,
that: (i) no Person involved in the sale of Registrable Securities which Person is guilty of fraudulent misrepresentation (within
the meaning of Section 11(f) of the 1933 Act) in connection with such sale shall be entitled to contribution from any Person involved
in such sale of Registrable Securities who was not guilty of fraudulent misrepresentation; and (ii) contribution by any seller
of Registrable Securities shall be limited in amount to the amount of net proceeds received by such seller from the sale of such
Registrable Securities pursuant to such Registration Statement.

 

8. Reports
Under the 1934 Act.

 

With a view to making
available to the Investors the benefits of Rule 144, the Company agrees to, while any Investor owns any Registrable Securities
and commencing with the Nasdaq Listing:

 

(a) make and keep
public information available, as those terms are understood and defined in Rule 144;

 

(b) file with
the SEC in a timely manner all reports and other documents required of the Company under the 1933 Act and the 1934 Act so long
as the Company remains subject to such requirements and the filing of such reports and other documents is required for the applicable
provisions of Rule 144; and

 

    16

     

    

 

(c) furnish to
each Investor so long as such Investor owns Registrable Securities, promptly upon request, (i) a written statement by the Company,
if true, that it has complied with the reporting requirements of Rule 144, the 1933 Act and the 1934 Act, (ii) following request
of such Investor, a copy of the most recent annual or quarterly report of the Company and such other reports and documents so filed
by the Company (which may be delivered by email) and (iii) such other information as may be reasonably requested to permit the
Investors to sell such securities pursuant to Rule 144 without registration.

 

9. Assignment
of Registration Rights.

 

The rights under this
Agreement shall be automatically assignable by the Investors to any transferee of all or any portion of such Investor’s Registrable
Securities if: (i) the Investor agrees in writing with the transferee or assignee to assign such rights, and a copy of such agreement
is furnished to the Company within a reasonable time after such assignment; (ii) the Company is, within a reasonable time after
such transfer or assignment, furnished with written notice of (a) the name and address of such transferee or assignee, and (b)
the securities with respect to which such registration rights are being transferred or assigned; and (iii) at or before the time
the Company receives the written notice contemplated by clause (ii) of this sentence the transferee or assignee agrees in writing
with the Company to be bound by all of the provisions contained herein.

 

10. Amendment
of Registration Rights.

 

Provisions of this Agreement
may be amended and the observance thereof may be waived (either generally or in a particular instance and either retroactively
or prospectively), only with the written consent of the Company and the Required Holders; provided that any such amendment or waiver
that complies with the foregoing but that disproportionately, materially and adversely affects the rights and/or obligations of
any Investor relative to the comparable rights and/or obligations of the other Investors shall require the prior written consent
of such adversely affected Investor. Any amendment or waiver effected in accordance with this Section 10 shall be binding upon
each Investor and the Company. No such amendment shall be effective to the extent that it applies to less than all of the holders
of the Registrable Securities. No consideration shall be offered or paid to any Person to amend or consent to a waiver or modification
of any provision of this Agreement unless the same consideration (other than the reimbursement of legal fees) also is offered to
all of the parties to this Agreement.

 

11. Miscellaneous.

 

(a) A Person is
deemed to be a holder of Registrable Securities whenever such Person owns or is deemed to own of record such Registrable Securities.
If the Company receives conflicting instructions, notices or elections from two or more Persons with respect to the same Registrable
Securities, the Company shall act upon the basis of instructions, notice or election received from such record owner of such Registrable
Securities.

 

    17

     

    

 

(b) Any notices,
consents, waivers or other communications required or permitted to be given under the terms of this Agreement must be in writing
and will be deemed to have been delivered: (i) upon receipt, when delivered personally; (ii) upon delivery, when sent by facsimile
(provided confirmation of transmission is mechanically or electronically generated and kept on file by the sending party), (iii)
upon delivery, when sent by electronic mail (provided
that the sending party does not receive an automated rejection notice); or (iv) one Business Day after deposit with a nationally
recognized overnight delivery service, in each case properly addressed to the party to receive the same. The addresses, facsimile
numbers and e-mail addresses for such communications shall be:

 

If to the Company:

 

Bonus
BioGroup Ltd.,

Israeli
Public Company 520039777,

Of
the Matam Advanced Technology Park, 

Building
8B,

P.O.B.
15143, Haifa 31905, Israel

 

with
a copy (for informational purposes only) to:

 

Efrati Galili Confino
& Co.

Address: 28 Haarbaa
St. | Haarbaa South Tower | 19th floor

Tel Aviv 6473925

Attention: Gil Lavron,
Adv.

Email: gil@egl.co.il

 

If to an Investor, to its address, facsimile
number or email address set forth on the Schedule of Investors attached hereto, with copies to such Buyer’s representatives as
set forth on the Schedule of Investors, or to such other address, facsimile number and/or email address to the attention of such
other Person as the recipient party has specified by written notice given to each other party five (5) days prior to the effectiveness
of such change. Written confirmation of receipt (A) given by the recipient of such notice, consent, waiver or other communication,
(B) mechanically or electronically generated by the sender’s facsimile machine or e-mail transmission containing the time, date,
recipient facsimile number or e-mail address and an image of the first page of such transmission or (C) provided by a courier or
overnight courier service shall be rebuttable evidence of personal service, receipt by facsimile or receipt from a nationally recognized
overnight delivery service in accordance with clause (i), (ii) or (iii) above, respectively.

 

(c) Failure of
any party to exercise any right or remedy under this Agreement or otherwise, or delay by a party in exercising such right or remedy,
shall not operate as a waiver thereof.

 

    18

     

    

 

(d) All questions
concerning the construction, validity, enforcement and interpretation of this Agreement shall be governed by the internal laws
of the State of New York, without giving effect to any choice of law or conflict of law provision or rule (whether of the State
of New York or any other jurisdictions) that would cause the application of the laws of any jurisdictions other than the State
of New York. Each party hereby irrevocably submits to the exclusive jurisdiction of the state and federal courts sitting in The
City of New York, Borough of Manhattan, for the adjudication of any dispute hereunder or in connection herewith or with any transaction
contemplated hereby or discussed herein, and hereby irrevocably waives, and agrees not to assert in any suit, action or proceeding,
any claim that it is not personally subject to the jurisdiction of any such court, that such suit, action or proceeding is brought
in an inconvenient forum or that the venue of such suit, action or proceeding is improper. Each party hereby irrevocably waives
personal service of process and consents to process being served in any such suit, action or proceeding by mailing a copy thereof
to such party at the address for such notices to it under this Agreement and agrees that such service shall constitute good and
sufficient service of process and notice thereof. Nothing contained herein shall be deemed to limit in any way any right to serve
process in any manner permitted by law. EACH PARTY HEREBY IRREVOCABLY WAIVES ANY RIGHT IT MAY HAVE, AND AGREES NOT TO REQUEST,
A JURY TRIAL FOR THE ADJUDICATION OF ANY DISPUTE HEREUNDER OR IN CONNECTION HEREWITH OR ARISING OUT OF THIS AGREEMENT OR ANY TRANSACTION
CONTEMPLATED HEREBY.

 

(e) If any provision
of this Agreement is prohibited by law or otherwise determined to be invalid or unenforceable by a court of competent jurisdiction,
the provision that would otherwise be prohibited, invalid or unenforceable shall be deemed amended to apply to the broadest extent
that it would be valid and enforceable, and the invalidity or unenforceability of such provision shall not affect the validity
of the remaining provisions of this Agreement so long as this Agreement as so modified continues to express, without material change,
the original intentions of the parties as to the subject matter hereof and the prohibited nature, invalidity or unenforceability
of the provision(s) in question does not substantially impair the respective expectations or reciprocal obligations of the parties
or the practical realization of the benefits that would otherwise be conferred upon the parties. The parties will endeavor in good
faith negotiations to replace the prohibited, invalid or unenforceable provision(s) with a valid provision(s), the effect of which
comes as close as possible to that of the prohibited, invalid or unenforceable provision(s).

 

(f) This Agreement,
the other Transaction Documents (as defined in the Share Purchase Agreement) and the instruments referenced herein and therein
constitute the entire agreement among the parties hereto with respect to the subject matter hereof and thereof. There are no restrictions,
promises, warranties or undertakings, other than those set forth or referred to herein and therein. This Agreement, the other Transaction
Documents and the instruments referenced herein and therein supersede all prior agreements and understandings among the parties
hereto with respect to the subject matter hereof and thereof.

 

(g) Subject to
the requirements of Section 9, this Agreement shall inure to the benefit of and be binding upon the permitted successors and assigns
of each of the parties hereto.

 

(h) The headings
in this Agreement are for convenience of reference only and shall not limit or otherwise affect the meaning hereof.

 

    19

     

    

 

(i) This Agreement
may be executed in identical counterparts, each of which shall be deemed an original but all of which shall constitute one and
the same agreement. This Agreement, once executed by a party, may be delivered to the other party hereto by facsimile transmission
or scanned via e-mail of a copy of this Agreement bearing the signature of the party so delivering this Agreement.

 

(j) Each party
shall do and perform, or cause to be done and performed, all such further acts and things, and shall execute and deliver all such
other agreements, certificates, instruments and documents, as any other party may reasonably request in order to carry out the
intent and accomplish the purposes of this Agreement and the consummation of the transactions contemplated hereby.

 

(k) All consents
and other determinations required to be made by the Investors pursuant to this Agreement shall be made, unless otherwise specified
in this Agreement, by the Required Holders.

 

(l) The language
used in this Agreement will be deemed to be the language chosen by the parties to express their mutual intent and no rules of strict
construction will be applied against any party.

 

(m) This Agreement
is intended for the benefit of the parties hereto and their respective permitted successors and assigns, and is not for the benefit
of, nor may any provision hereof be enforced by, any other Person.

 

(n) The obligations
of each Investor hereunder are several and not joint with the obligations of any other Investor, and no provision of this Agreement
is intended to confer any obligations on any Investor vis-à-vis any other Investor. Nothing contained herein, and no action
taken by any Investor pursuant hereto, shall be deemed to constitute the Investors as a partnership, an association, a joint venture
or any other kind of entity, or create a presumption that the Investors are in any way acting in concert or as a group with respect
to such obligations or the transactions contemplated herein.

 

[Signature Page Follows]

 

    20

     

    

 

IN WITNESS WHEREOF,
each Investor and the Company have caused their respective signature page to this Registration Rights Agreement to be duly executed
as of the date first written above.

 

	 	COMPANY:
	 	 
	 	BONUS BIOGROUP LTD.
	 	 	 	 
	 	By:	         
	 	 	Name:	 
	 	 	Title:	 

 

     

     

    

 

IN WITNESS WHEREOF,
each Investor and the Company have caused their respective signature page to this Registration Rights Agreement to be duly executed
as of the date first written above.

 

	 	WIZE PHARMA, INC.
	 	 	 	 
	 	By:	       
	 	 	Name:	 
	 	 	Title:	 

 

[Signature Page to Registration Rights Agreement]

 

     

     

    

 

SCHEDULE OF INVESTORS

 

	
         

        Investor
	 	
        Investor Address, Facsimile Number

        and Email
	 	Investor’s Representative’s Address, 

Facsimile Number and Email
	 	 	 	 	 
	
        Wize Pharma Inc.

         
	 	
        Wize Pharma, Inc.

        24 Hanagar Street

        Hod Hasharon 4527708

        Israel

        Telephone: 972 (72) 260-0536

        Facsimile: 972 (72) 260-0536

        Attention: Or Eisenberg

        E-mail: or@wizepharma.com
	 	
        

        Goldfarb Seligman & Co.

        98 Yigal Alon Street

        Tel Aviv, Israel 6789141

        Attention: Ido Zemach

        Telephone: +972-3-608-9989

        Email: ido.zemach@goldfarb.com

 

     

     

    

 

EXHIBIT A

 

SELLING SHAREHOLDERS

 

The Ordinary Shares
being offered by the selling shareholders are those previously issued to the selling shareholders and those shares issuable under
the Share Purchase Agreement and Exchange Agreement. For additional information regarding the issuances of the Ordinary Shares,
see [“Private Placement of Ordinary Shares”] above. We are registering the Ordinary Shares in order to permit the selling
shareholders to offer the shares for resale from time to time. Except for the ownership of the Ordinary Shares, pursuant to the
Share Purchase Agreement and Exchange Agreement, the selling shareholders have not had any material relationship with us within
the past three years.

 

The table below lists
the selling shareholders and other information regarding the beneficial ownership of the Ordinary Shares by each of the selling
shareholders. The second column lists the number of Ordinary Shares beneficially owned by each selling shareholder, based on its
ownership of the Ordinary Shares, as of ________, 2020.

 

The third column lists
the Ordinary Shares being offered by this prospectus by the selling shareholders.

 

In accordance with
the terms of a registration rights agreement with the holders of the Ordinary Shares, this prospectus generally covers the resale
of at least a number of Ordinary Shares equal to the sum of (i) the number of Ordinary Shares issued, and (ii) the maximum number
of Ordinary Shares issued and issuable pursuant to the Share Purchase Agreement and Exchange Agreement as of the Trading Day immediately
preceding the date the registration statement is initially filed with the SEC, all subject to adjustment as provided in the registration
rights agreement. Because the number of Ordinary Shares may be adjusted, the number of shares that will actually be issued may
be more or less than the number of shares being offered by this prospectus. The fourth column assumes the sale of all of the shares
offered by the selling shareholders pursuant to this prospectus.

 

    Annex I-1

     

    

 

	Name of Selling Shareholder	 	Number of Shares of Common Share Owned Prior to Offering	 	Maximum Number of Shares of Common Share to be Sold Pursuant to this Prospectus	 	Number of Shares of Common Share Owned After Offering
	 	 	 	 	 	 	 
	Wize Pharma Inc.	 	 	 	 	 	 

 

    Annex I-2

     

    

 

PLAN OF DISTRIBUTION

 

We are registering
the Ordinary Shares previously issued and the Ordinary Shares issuable under the Share Purchase Agreement and Exchange Agreement
as of the Trading Day immediately preceding the date the registration statement is initially filed with the SEC, to permit the
resale of these Ordinary Shares by the holders of these securities from time to time after the date of this prospectus. We will
not receive any of the proceeds from the sale by the selling shareholders of the Ordinary Shares. We will bear all fees and expenses
incident to our obligation to register the Ordinary Shares.

 

The selling shareholders
may sell all or a portion of the Ordinary Shares beneficially owned by them and offered hereby from time to time directly or through
one or more underwriters, broker-dealers or agents. If the Ordinary Shares are sold through underwriters or broker-dealers, the
selling shareholders will be responsible for underwriting discounts or commissions or agent’s commissions. The Ordinary Shares
may be sold in one or more transactions at fixed prices, at prevailing market prices at the time of the sale, at varying prices
determined at the time of sale, or at negotiated prices. These sales may be effected in transactions, which may involve crosses
or block transactions,

 

		●	on
                                         any national securities exchange or quotation service on which the securities may be
                                         listed or quoted at the time of sale;

 

		●	in the over-the-counter market;

 

		●	in transactions other than on these exchanges or systems
or in the over-the-counter market;

 

		●	ordinary brokerage transactions and transactions in which
the broker-dealer solicits purchasers;

 

		●	block trades in which the broker-dealer will attempt to
sell the shares as agent but may position and resell a portion of the block as principal to facilitate the transaction;

 

		●	purchases by a broker-dealer as principal and resale by
the broker-dealer for its account;

 

		●	an exchange distribution in accordance with the rules of
the applicable exchange;

 

		●	privately negotiated transactions;

 

		●	sales pursuant to Rule 144;

 

		●	broker-dealers may agree with the selling securityholders
to sell a specified number of such shares at a stipulated price per share;

 

		●	a combination of any such methods of sale; and

 

		●	any other method permitted pursuant to applicable law.

 

    Annex I-3

     

    

 

If the selling shareholders
effect such transactions by selling Ordinary Shares to or through underwriters, broker-dealers or agents, such underwriters, broker-dealers
or agents may receive commissions in the form of discounts, concessions or commissions from the selling shareholders or commissions
from purchasers of the Ordinary Shares for whom they may act as agent or to whom they may sell as principal (which discounts, concessions
or commissions as to particular underwriters, broker-dealers or agents may be in excess of those customary in the types of transactions
involved).

 

The selling shareholders
may pledge or grant a security interest in some or all of the Ordinary Shares owned by them and, if they default in the performance
of their secured obligations, the pledgees or secured parties may offer and sell the Ordinary Shares from time to time pursuant
to this prospectus or any amendment to this prospectus under Rule 424(b)(3) or other applicable provision of the Securities Act
of 1933, as amended, amending, if necessary, the list of selling shareholders to include the pledgee, transferee or other successors
in interest as selling stockholders under this prospectus. The selling shareholders also may transfer and donate the Ordinary Shares
in other circumstances in which case the transferees, donees, pledgees or other successors in interest will be the selling beneficial
owners for purposes of this prospectus. The selling shareholders and any broker-dealer participating in the distribution of the
shares may be deemed to be “underwriters” within the meaning of the Securities Act, and any commission paid, or any discounts
or concessions allowed to, any such broker-dealer may be deemed to be underwriting commissions or discounts under the Securities
Act. At the time a particular offering of the shares is made, a prospectus supplement, if required, will be distributed which will
set forth the aggregate amount of Ordinary Shares being offered and the terms of the offering, including the name or names of any
broker-dealers or agents, any discounts, commissions and other terms constituting compensation from the selling shareholders and
any discounts, commissions or concessions allowed or reallowed or paid to broker-dealers.

 

Under the securities
laws of some states, the Ordinary Shares may be sold in such states only through registered or licensed brokers or dealers. In
addition, in some states the Ordinary Shares may not be sold unless such shares have been registered or qualified for sale in such
state or an exemption from registration or qualification is available and is complied with.

 

There can be no assurance
that any selling shareholder will sell any or all of the Ordinary Shares registered pursuant to the registration statement, of
which this prospectus forms a part.

 

The selling shareholders
and any other person participating in such distribution will be subject to applicable provisions of the Securities Exchange Act
of 1934, as amended, and the rules and regulations thereunder, including, without limitation, Regulation M of the Exchange Act,
which may limit the timing of purchases and sales of any of the shares by the selling shareholders and any other participating
person. Regulation M may also restrict the ability of any person engaged in the distribution of the Ordinary Shares to engage in
market-making activities with respect to the shares. All of the foregoing may affect the marketability of the Ordinary Shares and
the ability of any person or entity to engage in market-making activities with respect to the Ordinary Shares.

 

We will pay all expenses
of the registration of the Ordinary Shares pursuant to the registration rights agreement, estimated to be $[     ]
in total, including, without limitation, Securities and Exchange Commission filing fees and expenses of compliance with state securities
or “blue sky” laws; provided, however, that a selling shareholder will pay all underwriting discounts and selling commissions,
if any. We will indemnify the selling shareholders against liabilities, including some liabilities under the Securities Act, in
accordance with the registration rights agreements, or the selling shareholders will be entitled to contribution. We may be indemnified
by the selling shareholders against civil liabilities, including liabilities under the Securities Act, that may arise from any
written information furnished to us by the selling shareholder specifically for use in this prospectus, in accordance with the
related registration rights agreement, or we may be entitled to contribution.

 

Once sold under the
registration statement, of which this prospectus forms a part, the Ordinary Shares will be freely tradable in the hands of persons
other than our affiliates.

 

 

Annex I-4

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00303-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00303-of-00352.parquet"}]]